Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events

Title: Baseline and on-statin treatment lipoprotein(a) levels predict cardiovascular events: An individual-patient-data meta-analysis of statin outcome trials

Article Type: Article

Corresponding Author: Dr. sotirios tsimikas, MD

Corresponding Author's Institution: UCSD

First Author: Peter Willeit, MD

Order of Authors: Peter Willeit, MD; Paul M Ridker, MD; Paul J Nestel , MD; John Simes, MD; Andrew M Tonkin, MD, PhD; Terje R Pedersen, MD; Gregory G Schwartz, MD, PhD; Anders G Olsson, MD, PhD; Helen M Calhoun, MD; Christiane Drechsler, MD, PhD; Florian Kronenberg, PhD; Christoph Wanner, MD; Samia Mora, MD; Anastasia Lesogor, MD; sotirios tsimikas, MD

Abstract: Background: Elevated lipoprotein(a) [Lp(a)] is a genetic risk factor for cardiovascular disease (CVD) in general population studies, but its contribution to CVD risk in patients with established CVD or on statin therapy is uncertain.
Methods: Patient-level data from seven randomized placebo-controlled statin outcomes trials were collated and harmonized to calculate hazard ratios for CVD, defined as fatal or non-fatal coronary heart disease, stroke, or revascularisation procedures. Hazard ratios for CVD were estimated within each trial across pre-defined Lp(a) groups (15-<30, 30-<50, and ≥50 vs. <15 mg/dL), before pooling estimates using multivariate random-effects meta-analysis.
Findings: Analyses included data for 29069 patients with repeat Lp(a) measurements (mean age 62 years; 28% female; 5751 events during 95576 person-years at risk). Initiation of statin therapy reduced low-density-lipoprotein cholesterol (mean change [95% CI]: -39% [-43, -35]) without a significant change in Lp(a). Associations of baseline and on-statin treatment Lp(a) with CVD risk were approximately linear with increased risk at Lp(a) values ≥30 mg/dL for baseline Lp(a) and ≥50 mg/dL for on-statin Lp(a). Age- and sex-adjusted hazard ratios across Lp(a) groups [referent: Lp(a) <15 mg/dL] were 1·04 (0·91, 1·18), 1·11 (1·00, 1·22), and 1·31 (1·08, 1·58) for baseline Lp(a), and 0·94 (0·81, 1·10), 1·06 (0·94, 1·21), and 1·43 (1·15, 1·76) for on-statin Lp(a). Hazard ratios were virtually identical after further adjustment for prior CVD, diabetes, smoking, systolic blood pressure, low-density-lipoprotein cholesterol, and high-density-lipoprotein cholesterol. The association of on-statin Lp(a) with CVD risk was stronger than for on-placebo Lp(a) (interaction P=0·010) and was more pronounced at younger ages (interaction P=0·008) without effect modification by any other patient-level or study-level characteristics.
Interpretation: In this individual-patient meta-analysis of statin-treated patients, elevated baseline and on-statin Lp(a) showed an independent, approximately linear relationship with CVD risk. This study provides a rationale for testing the Lp(a) lowering hypothesis in CVD outcomes trials.

Responses to comments of editors and reviewers

Note: Lines numbers listed in this document are for the version of the manuscript with track changes.

Editors' comments

Comment #1:
In responses to reviewers' points, provide text changes together with line numbers.

Response: As requested, we provide the text changes together with line numbers

Comment #2:
When interpreting editorial points made by reviewers, please remember we will further edit the final manuscript if accepted.

Response: Thank you for pointing this out to us.

Comment #3:
Please indicate any authors who are full professors.

Response: In the revised list of affiliations of the manuscript (**lines 8-28**), it is now specified who of the co-authors are full professors.

Comment #4:
For randomised trials please follow the CONSORT reporting guidelines http://www.consort-statement.org and include a CONSORT checklist.

Response: Our study was a meta-analysis evaluating the association of Lp(a) with disease risk of clinical trial data and not a primary report of a clinical trial reporting on the effect of an intervention on disease risk. We therefore believe this point does not apply to our study; nevertheless, in **Supplementary Table 2**, we provide a flow chart designed per CONSORT recommendations showing – for each trial – the numbers of people who were assessed for eligibility, were randomised, had missing Lp(a), were included in the analysis, and developed the CVD outcome during follow-up.

Comment #5:
Please follow CONSORT for abstracts (eg method of randomisation).

Response: Please see reply to editorial comment #4.

Comment #6:
At the end of the methods section please state the role of the funder in: data collection, analysis, interpretation, writing of the manuscript and the decision to submit. Please also state which author(s) had access to all the data, and which author(s) were responsible for the decision to submit the manuscript etc.

Response: We report this information on **lines 166-169** of the revised manuscript.

Comment #7:
Please give 95% confidence intervals for hazard ratios/odds ratios.

Response: Done.

1

Comment #8:
Limit summary to pre-defined primary endpoints and safety endpoints.

Response: Done.

Comment #9:
Report all outcomes specified in the protocol.

Response: We confirm that we report on all outcomes pre-specified in the statistical analysis plan for this project (developed prior to any combined analyses being undertaken, but after results of some trials were known).

Comment #10:
Please explain any deviations from the protocol.

Response: There were no deviation from the pre-specified statistical analysis plan of this project.

Comment #11:
Clearly denote analyses of exploratory outcomes as post-hoc.

Response: Done.

Comment #12:
P values should be exact to 4 decimal places (eg p<0.0001). Two decimals are acceptable in tables for non-significant p-values.

Response: Done.

Comment #13:
Please provide absolute numbers to accompany all percentages.

Response: We have revised the text in **lines 172-175** accordingly.

Comment #14:
Please provide numbers at risk for Kaplan-Meier plots.

Response: As requested, the Kaplan-Meier plot in this document (**Response Figure 1**) is provided together with numbers at risk. The main manuscript does not contain Kaplan-Meier plots.

Comment #15:
Please provide the text, tables and figures in an editable format.

Response: Done.

Comment #16:
Ensure that figures conform with the Lancet artwork guidelines.

Response: Done.

Comment #17:
Include a maximum of six main figures or tables, moving others to the web appendix.

Response: Done.

Comment #18:
Provide a research in context panel.

    Response: The research context panel has been updated to include a systematic review of prior evidence done.

Comment #19:
Provide signed authorship statements and conflict of interest forms and summarise authors' disclosures in the manuscript.

    Response: Done.

Comment #20:
Provide statements for any personal communication and for any named person in the acknowledgements saying that they agree to be acknowledged.

    Response: Done.

Comment #21:
Add a statement of author contributions at the end of the text.

    Response: Already done.

Comment #22:
Please ensure that there is a section in the Methods section confirming ethics approval and consent from all patients has been obtained.

    Response: We now state in the methods section on **line 110** that: "All contributing trials have obtained ethics approval and patients' informed consent."

Comment #23:
Confirm that all authors have seen and approved of the final text.

    Response: The corresponding authors Peter Willeit and Sam Tsimikas confirm that all authors have seen and approved the final text.

Comment #24:
Avoid endnotes.

    Response: Done.

Comment #25:
Please note our guideline length for research articles is 3000 words. Allowing for additional material requested by reviewers and editors we can allow a little leeway but we hope for final manuscript below 3500 words (4500 words for RCTs).

    Response: Done.

Comment #26:
Provide a revised manuscript, a tracked changes version showing the changes made, and a point-by-point response to ALL EDITORS' and reviewers' comments - typed immediately following each specific point.

    Response: Done.

Avoid boxes for replies.

   Response: Done.

Reviewer #1

This analysis addresses an important question regarding Lp(a) risk in patients treated with statins. Thus, these data differ from the Lp(a) Collaboration Study. The use of patient specific data, statistical methods and analysis are a strength. The authors use these data to present a case for the Novartis antisense therapy for Lp(a). Overall, the data is important, but the commercial link is overdone in the view of this Reviewer.

Comment #1:
In the introduction, revise the statement on the limitation of single statin RCT analyses.

   Response: We have now clarified on **lines 86-93** of the revised manuscript that "a major limitation of all post hoc studies reporting Lp(a) levels and outcomes is that they involved only a small number of patients with Lp(a) values above 50 mg/dL and therefore were uniformly underpowered to test the hypothesis that elevated Lp(a) levels are associated with increased CVD risk in the setting of statin therapy or prior history of CVD."

Comment #2:
Discussion. Page 8. Paragraph 2. Lines 2-3. A small angiographic study. Provide reference. If the authors are using FATS or HATS as a reference, how do they account for the reduction in Lp(a) in the niacin arm as a confounder?

   Response: We used the post-hoc analysis of FATS as a reference (Maher et al JAMA 1995, now cited). The study combined three treatment arms (i.e. lovastatin 40 mg daily plus colestipol 30 g daily, niacin 4 g daily plus colestipol, and placebo) and compared LDL-C non-responders (+6%, n=36) with responders (-40%, n=84). The baseline and on-treatment Lp(a) levels were not significantly different between LDL-C responders and non-responders (37 vs. 35 mg/dL at baseline; 34 vs. 29 mg/dL on-treatment). Therefore, this appears to address potential confounding. However, our point is that the paper's conclusion may be faulty due to low power, low baseline Lp(a), and type-2 error. It is contradicted by our much larger study. This paper has been cited very frequently and has made it into treatment paradigms of the practicing physician that, if LDL-C is controlled, Lp(a) is not a risk factor. This had likely led to many physicians not measuring or even thinking about Lp(a) as a risk factor. The potential adverse impact to patients of this underpowered post-hoc analysis cannot be quantitated but is likely significant.

   In further proof, both FOURIER and ODYSSEY OUTCOMES have now presented (but not published yet) their data and both show elevated baseline Lp(a) remains a risk factor even with exceedingly low LDL-C <50 mg/dL.

   We have added the following statement to the revised discussion (**lines 309-314**): "In support of our observation in this study, the trials FOURIER (European Atherosclerosis Society, May 2018) and ODYSSEY OUTCOMES (International Atherosclerosis Society, June 2018) have recently presented preliminary findings of their data, both showing that elevated baseline Lp(a) remains a risk factor even with on-treatment LDL-C <50 mg/dL in patients treated with statins and PCSK9 inhibitors." Moreover, data presented from ODYSSEY OUTCOMES indicate that lowering of Lp(a) with alirocumab is associated with reduced major adverse cardiac outcomes, independent of the effects of alirocumab on LDL-C.

Omit the speculative comment on association shapes and clinical benefit at different levels of Lp(a) concentration.

> **Response:** We have now omitted this comment on **lines 319-321** of the revised manuscript.

Reviewer #2

Lipoprotein(a) (Lp(a)) is one of the last bastions in lipid management and new potent therapies for lowering Lp(a) will be a major focus of future clinical trials. Nine of ten WHO criteria to justify screening for Lp(a) are met and reduction of ASCVD risk with intervention is the missing link that could revolutionize lipid management in high risk patients and their families in the next decade. Most of the observational evidence supporting Lp(a) as a risk factor for ASCVD (and aortic stenosis to lesser extent) comes from primary prevention cohorts. The present analysis from the Lp(a) Studies Collaboration shows that in patients derived from several large statin trials Lp(a) remains an independent risk factor for incident events. This finding is crucially important, because of antecedent uncertainties in part related to faulty or biased analyses. The results of this powerful analysis will pave the way for future intervention trials with ASO and siRNa directed at apo(a).

Comment #1:
The selection process for the 29,069 patients from the seven statin trials might have biased the results. What re-assurance can you provide for lack of bias from the study design adopted?

> **Response:** As noted by the reviewer, the seven statin trials we analysed involved 29,069 patients with Lp(a) measurements and 15,975 patients without Lp(a) measurements. In none of these trials were patients selected on the basis of Lp(a) levels. The choice for selecting patients for Lp(a) assessment in the current analysis was entirely based on the availability of sufficient blood sample at baseline and/or follow-up. The analysis shown in revised **Supplementary Table 1** confirms that there were minimal differences in baseline characteristics of patients with or without Lp(a) measurements. This is now also stated in the methods section, **lines 116-118**.

Comment #2:
Clarify why results differ from those of the previous study by O'Donoghue *et al* in JACC.

> **Response:** Associations in the three trials reported by O'Donoghue *et al* (PROVE-IT, CARE, and PEACE) were somewhat weaker than our analysis (see summary in **Response Table 1** below). Three features crucially distinguish our analysis from the O'Donoghue paper. First, the three trials in the paper by O'Donoghue *et al* recorded a low number of incident events (i.e. 191 in PROVE-IT, 15 in CARE, and 343 in PEACE vs. 5751 in our analysis), leading to limited statistical power and wide 95% confidence intervals of estimated hazard ratios. Second, in contrast to our analysis which defined Lp(a) categories informed by ESC/EAS guideline recommendations (Eur Heart J 2016;37:2999–3058) (i.e. <15, 15-<30, 30-<50, and ≥50 mg/dL), O'Donoghue *et al* defined Lp(a) categories in each trial differently (i.e. trial-specific quintiles). Third, the boundaries of these Lp(a) categories were lower than the ones used in our analysis (see **Response Table 1**) and hence a threshold effect at high Lp(a) concentrations might have been missed. It has to be noted that the O'Donoghue paper also includes a meta-analysis of eight additional trials, but neither of these additional trials evaluated a statin intervention.
>
> We have now added the following statement to the discussion (**lines 272-276**) to address this important point: "In contrast to a previous analysis of individual-patient data by O'Donoghue et al, our study afforded higher statistical power because it involved >10 times more CVD events, and hence was able to characterise associations with high Lp(a) concentrations more precisely. Moreover, the present analysis used clinically-relevant Lp(a) categories informed by guideline recommendations, as opposed to trial-specific quintiles."

> **Response Table 1.** Comparison of results from the paper by O'Donoghue *et al* to our analysis.

Trial	No. of patients / events	Comparison groups	Hazard ratio (95% CI)
PROVE-IT	2529 / 191	<1.8 vs. >31.3 mg/dL	1.00 (0.63-1.59)
CARE	785 / 15	<3 vs. ≥41 mg/dL	1.08 (0.69-1.68)
PEACE	3394 / 343	<4.6 vs. >49 mg/dL	1.07 (0.75-1.53)
Our analysis	29069 / 5751	<15 vs. ≥50 mg/dL	1.35 (1.11-1.66)

Comment #3:

Index event bias can plague the assessment of a risk factor for recurrent events. This can be an issue in secondary prevention trials. Was this a problem and how was it addressed?

Response: We expect that effects of index event bias are limited in our present analysis because: (i) we observed similarly strong associations between Lp(a) and CVD risk in people with and without baseline CVD; (ii) we observed concordant correlations between Lp(a) and other CVD risk factors in people with and without baseline CVD, whereas index event bias typically characterised by such correlations being directionally discordant (**Response Table 2**); and (iii) we employed multivariable adjustment, which can partial control index event bias (discussed in JAMA 2011; 305(8): 822–823) Still, because we cannot entirely rule out presence of index event bias, we now state in the limitation section of the discussion on **lines 338-340** that: "we cannot rule out that index event bias may have attenuated effect sizes in secondary prevention trials, although the scope of this bias was reduced by employment of multivariable adjustment."

Response Table 2. Correlates of Lp(a) at baseline in patients with and without pre-existing CVD.

Clinical variables	% difference in Lp(a) (95% CI) per SD higher value of clinical variables or compared to reference group of clinical variables	
	Patients without CVD at baseline (n=13817)	Patients with CVD at baseline (n=15252)
Age	1% (-2 to 4)	-1% (-3 to 1)
Sex, females vs. males	14% (-4 to 36)	8% (2 to 15)
Diabetes, yes vs. no	-41% (-60 to -11)	-15% (-22 to -8)
Smoking, yes vs. no	5% (-0 to 11)	-2% (-7 to 4)
SBP	-1% (-6 to 4)	-3% (-6 to -1)
LDL-C$_{corr}$	-17% (-27 to -6)	-16% (-27 to -3)
HDL-C	9% (4 to 14)	6% (0 to 11)
BMI	-4% (-6 to -2)	-8% (-11 to -4)

For categorical clinical variables, % differences shown are for females compared to males, patients with diabetes compared to those without, and patients who were smokers compared to those who were not.

Comment #4:

Lp(a) is notoriously difficult to assay accurately. Isoform independent assays are essentially non-existent, despite apparent claims to the contrary. What assays were employed in the various studies and how were the mass values standardised? How long were samples stored for and under what conditions; was this uniform across studies?

Response: The assays used are noted below in **Response Table 3**. All studies with two exceptions used commercially available assays used in routine clinical care, which disposed of acceptable metrics of accuracy and precision. MIRACL used a UCSD validated in-house ELISA, and 4D applied an in-house ELISA with a combination of poly- and monoclonal antibodies used in many dozens of studies before. As shown in **Response Table 3** below, duration of storage of blood samples before Lp(a) measurement was variable within and between trials, ranging from immediate processing to storage for up to 18 years. We did note this previously as a limitation and have now further expanded this point to take your comments into consideration (discussion section, **lines 332-334**).

Response Table 3. Assays used to measure Lp(a).

Trial	Assay manufacturer (assay type)	Sample	Storage	Storage

		type	time	temperature
AFCAPS	NR	NR	NR	NR
CARDS	Technoclone (Immunoturbidimetric assay)	Serum	5-9 yrs	-70°C
4D	In-house (ELISA)	Serum	10 yrs	-70°C
JUPITER	Randox (Immunoturbidimetric assay)	Plasma	6-10 yrs	-70°C
LIPID	Abbott Diagnostics (Latex particle immunoassay)	Plasma	17-18 yrs	-70°C
MIRACL	In-house (ELISA)	Plasma	5 yrs	-70°C
4S	Pharmacia (Radioimmunoassay)	Serum	0-1.8 yrs	-70°C

NR=not reported.

Comment #5:

The studies included in this analysis were heterogeneous: primary and secondary stable coronary prevention; diabetics; CKD on hemodialysis; an ACS group. The MIRACL study was a short trial and measurement of Lp(a) in an ACS setting may be unreliable. Was this accounted for in the statistical analyses?

> **Response:** It is correct that we investigated the association of baseline and on-statin Lp(a) with CVD risk in a broad range of types of patient populations, enhancing the generalisability of our findings and their clinical translation. To account for the differences in population types in our analysis, we estimated (and provide in **Supplementary Table 5**) hazard ratios within each study separately, before calculating a pooled estimate using random-effects meta-analysis (which in contrast to fixed-effects models relaxes the strong assumption that the studies estimate the same true effect and rather estimates a distribution of effects). Besides a more pronounced association at younger ages, subsidiary meta-regression analyses showed similar magnitudes of associations according to prior CVD, diabetes, or length of follow-up (for detailed results, please see **Supplementary Figure 2**), thereby leaving some of the between-study heterogeneity unexplained. In the revised discussion on **lines 340-342**, we therefore acknowledge that "our analysis identified moderate to high between-study heterogeneity, which could not be explained by baseline disease status (i.e. prior CVD or prior diabetes) nor by differing lengths of follow-up periods". Finally, in MIRACL, acute phase response effects on Lp(a) are unlikely to be significant because Lp(a) levels in the placebo group remained unchanged between the baseline to the 16-week assessment. In specific, the mean % change of Lp(a) in this timeframe was -0.7% (95% confidence interval: -3.2 to +1.9%; P=0.600).

Comment #6:

Assay heterogeneity can be addressed by genotyping apo(a) for CNV in K-IV2 or for the 2 Clarke SNPs. Do the authors have data on apo(a) gene variants in this cohort to corroborate their assertions or at least to check for the validity of their Lp(a) mass assay(s) and the back calculation of mass from apparent molar values, as was suggested in the methods.

> **Response:** LPA SNPs were not measured in these studies nor is DNA available to do so now. KIV2 repeats were measured in 4D, but this study only contributed 1249/29,069 patients. KIV-2 repeats also can only explain 25-50% of Lp(a) levels, so this is not likely to be an appropriate method to test assay heterogeneity.

Comment #7:

Did the authors examine heterogeneity of effect sizes by country of origin of participants in the trials? For example, in Europe a negative gradient in plasma Lp(a) levels has been described from north to south; were the results different in 4S from other trials?

> **Response:** This is an important point, but these data are not available for all the studies in the meta-analysis to perform this analysis.

Comment #8:

The relationship between Lp(a) and ASCVD may vary by gender; how was this adjusted for given wide differences in proportion of women in the trials; should the inferences from the analyses be guarded in women?

> **Response:** Our data indicates that the associations between high Lp(a) and CVD risk are <u>not</u> modified by sex. As shown in **Figure 3**, the hazard ratio for CVD with Lp(a) ≥50 mg/dL was 1.39 (1.19, 1.63) in men vs. 1.40 (1.12, 1.75) in females for baseline Lp(a) and 1.56 (1.26, 1.94) in men vs. 1.51 (1.19, 1.91) in females for on-statin Lp(a). P values for interaction were 0.91 for baseline Lp(a) and 0.79 for on-statin Lp(a).

Comment #9:
Lp(a) levels are often inversely related to plasma triglycerides (TGs), because theoretically apo(a) can transfer after secretion into plasma to TRL, especially in the postprandial status; while HDL-C is described and adjusted for, TG levels are not accounted for; can these data be provided?

> **Response:** We obtained triglyceride data from the trials CARDS, 4D, JUPITER, LIPID, MIRACL, and 4S. In analyses further adjusted for triglyceride levels, hazard ratios were virtually identical. These results have been added to **Supplementary Table 2** and are commented on in the results section (**line 210-213**).

Reviewer #3

Comment #1:
The authors excluded 35.5% of the data because these patients had missing Lp(a) measurements. Did these patients with missing data systematically differ from patients with Lp(a) data?

> **Response:** Revised **Supplementary Table 1** demonstrated that there were little differences in baseline characteristics of patients with or without Lp(a) measurements (also now commented on in the methods section, **lines 116-118**). The same point has been raised reviewer #2 (comment #1), where a more detailed response can be found.

Comment #2:
The authors reported imputing using a study-specific mixed model, can the authors detail this model? Was missing data mean-imputed based on this model?

> **Response:** For each trial separately, we fitted a linear mixed-effects model, as
>
> $$Y_{ij} = \beta_0 + \beta_1 \times S_i + \beta_2 \times t_{ij} + \beta_3 \times S_i \times t_{ij} + b_{0i} + \in_{ij}$$
>
> where Y_{ij} is the j-th log-transformed Lp(a) measurements for patient i, S_i is the assigned treatment group (1 if statin and 0 if placebo), and t_{ij} is the time from baseline of the j-th Lp(a) measurement. β_0, β_1, and β_3 are fixed effects, whereas b_{0i} is the random intercept allowed to vary at the patient level and $\in_{ij}$ is the random error term. For patients who had Lp(a) available only at one of the two time points (i.e. either at baseline or at follow-up), Lp(a) at the other time point was mean-imputed based on the expected Lp(a) change estimated from assigned treatment and duration of the trial. To help clarify the model specification, we have rephrased the methods section (**lines 122-128**) accordingly.

Comment #3:
How did the authors test the proportional hazards assumption? Did they test this assumption per-trial or over all trials?

Response: We tested the proportional assumption using on Schoenfeld residuals in models fitted separately to each study, before combining estimates in a meta-analysis. Detailed results of this analysis are provided in **Response Table 4**. We have expanded our statement on this in the revised manuscript on **line 145-146**: "The assumption for the proportionality of hazards was tested using Schoenfeld residuals and was met".

Response Table 4. Results from testing the PH assumption using Schoenfeld residuals.

Trial	Baseline Lp(a) χ^2 (d.f.)	Baseline Lp(a) P value	On-statin Lp(a) χ^2 (d.f.)	On-statin Lp(a) P value
AFCAPS	2.15 (3)	0.543	0.23 (3)	0.973
CARDS	3.48 (3)	0.324	0.55 (3)	0.907
4D	1.06 (3)	0.786	2.36 (3)	0.501
JUPITER	2.74 (3)	0.433	3.02 (3)	0.388
LIPID	1.54 (3)	0.674	4.83 (3)	0.185
MIRACL	5.51 (3)	0.138	3.13 (3)	0.372
4S	4.97 (3)	0.174	3.45 (3)	0.328
Overall	**21.44 (21)**	**0.432**	**17.57 (21)**	**0.676**

d.f.=degrees of freedom.

Comment #4:

In the results the authors report incidences per 1,000 person years. I'm not certain readers could easily digest how 55.3/1000 person years relates to risk.

Response: We agree with the reviewer that the interpretation of cumulative incidences over a specified time period (for example, cumulative 1-year CVD risk) would be more intuitive for readers than the interpretation of incidence rates. Nevertheless, because this project involved time-to-event data with different durations of follow-up contributed by each patient, we identified CVD incidence rate as the appropriate measure of disease incidence. In analogy to this, we chose to report hazard ratios rather than risk ratios as a measure of relative risk. If the reviewer or editorial team has a strong view on this, the results section containing the incidence rates (**lines 194-198**) could be omitted.

Comment #5:

How did CVD hazard rates differ by trial? May I ask to see Kaplan-Meier curves of CVD per trial? Even random-effects CpH models cannot overcome disparate baseline hazard rates between trials.

Response: Incidence rates varied substantially across trials, as expected given their different inclusion criteria (listed in **Table 1** of the manuscript). The incidence rates for CVD per 1,000 person-years (in descending order) are: 832.42 in MIRACL, 105.5 in 4D, 84.48 in LIPID, 68.65 in 4S, 17.97 in CARDS, 12.29 in AFCAPS, and 11.21 in JUPITER. A Kaplan-Meier plot with numbers-at-risk is provided in **Response Figure 1**. Because of these expected differences, we pre-specified in our analysis plan the use of a two-stage approach (rather than a single random-effects Cox model), whereby separate Cox models are fitted for each trial first, before study-specific effect estimates are pooled using random-effects meta-analysis.

Response Figure 1. Kaplan-Meier plots for incident CVD for each trial.

Number at risk

	0	1	2	3	4	5	6	7	8
AFCAPS	1005	1003	986	973	962	685	380	17	0
CARDS	2470	2424	2360	1927	1301	403	0	0	0
DDDD	1249	1019	746	479	253	103	0	0	0
JUPITER	9612	9533	4578	1555	558	1	0	0	0
LIPID	7863	7031	6449	5949	5483	4771	2122	67	0
MIRACL	2431	0	0	0	0	0	0	0	0
SSSS	4439	4088	3802	3538	3310	3073	30	0	0

AFCAPS — CARDS — DDDD — JUPITER — LIPID — MIRACL — SSSS

Comment #6:

Why did the authors choose to discretize Lp(a) rather than analyze as a continuous variable?

Response: We decided *a priori* to use Lp(a) categories in our analysis because we regard this as clinically more relevant. In particular, we aimed to provide clarity concerning any threshold effects for CVD risk. While the 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias considers CVD risk to be significant in people with Lp(a) values above 50 mg/dL (European Heart Journal 2016;37,2999–3058), many clinical laboratories and practitioners designate Lp(a) levels already above 30 mg/dL as being elevated (Arterioscler Thromb Vasc Biol 2015;35:996–1001). Furthermore, our focus on these guideline-informed categorisations of Lp(a) is also relevant to upcoming clinical trials because people with Lp(a) ≥50 mg/dL are considered a potential target subpopulation for therapeutic intervention specifically aimed at lowering Lp(a).

Comment #7:

The authors note this analysis is well-powered but do not present any formal power analysis.

Response: We have conducted a series of simulation studies to evaluate the statistical power in this random-effects meta-analysis. **Response Figure 2** plots statistical power as a function of the total number of participants to detect a hazard ratio of 1.4 or greater, assuming a similar distribution of patients across Lp(a) categories as in our dataset, a cumulative CVD incidence in the reference group similar as in our dataset (17.2%), and moderate-to-high between-study heterogeneity ($\tau^2 = 0.4$). By conducting a total of 1000 repetitions, the simulation evaluated statistical power in an modelled meta-analysis involving between 1000 and 40000 participants. Point estimates for statistical power are presented together with binomial confidence intervals. Details of the methods involved in this simulation are available in a separate methods paper (Journal of Statistical Software 2016;74(12)1-25; DOI: 10.18637/jss.v074.i12).

Response Figure 2. Statistical power according to total number of participants in a modelled meta-analysis (for modelling parameters, please see text above).

Reviewer #4

The investigators have conducted a meta-analysis using patient-level data from seven randomized placebo-controlled statin outcomes trials to evaluate CVD risk in patients on statin therapy. The investigators concluded that patients with elevated Lp(a) on statin therapy, primarily with levels of >50 mg/dL, are at a significantly higher risk of CVD. The hazard ratios for high Lp(a) at baseline and under statin therapy were of similar magnitude, reflecting that statin therapy may not appreciably affect Lp(a)-mediated risk in patients with elevated Lp(a). Overall, the methodology of the study conducted is robust.

My main concern is that I do not find the results to be surprising. There is prior evidence that the effect of statin therapy on Lp(a) levels is minimal. The LDL receptor does not seem to have a major role in lipoprotein(a) clearance; hence statins are generally ineffective in the reduction of lipoprotein(a) concentration. In the absence of such evidence, it is hard for me to even justify the premise of the study and it is hard to think of a valid reason why the investigators have gone through this effort of conducting an IPD meta-analysis. There is no other finding in this study which is novel. All of the findings described in the paper have been published previously by larger IPD meta-analyses.

Response: Although we agree with you on the issue of the statin therapy affecting Lp(a) levels and the role of the LDLR, the general thinking among clinicians has been that once one is on statin therapy, the need to measure Lp(a) or to consider it a risk factor is no longer relevant. Furthermore, several underpowered trials and observational studies have suggested as such (for instance, O'Donoghue *et al*, discussed in detail in our response to comment #2 of reviewer #2), while others suggested residual risk when Lp(a) is elevated. Thus, pending a randomized trial, this meta-analysis which specifically addressed the statin question and which has not been studied previously in secondary prevention cohorts is ideal to address this question. This is the first, adequately powered analysis to formally assess the effect of baseline and on-statin treatment effect that resolves this controversy with the best possible data pending an outcomes trial.

Technical points

Comment #1:

When you submit the revised paper, please provide: (i) one "clean" copy of your manuscript; (ii) one copy where your changes are highlighted (tracked changes); (iii) A separate, point by point response to the editorial and referee comments typed immediately following each specific point above. (iv) Any images and/or tables (even if no revisions have been made).

Response: Done.

Comment #2:

Please do NOT include a copy of your original manuscript. All text files should be supplied as MS Word files.

Response: Done.

Comment #3:

Please also supply the word count for the body of your paper and your abstract (word count for the body of your paper should not include abstract, references, figures or tables).

Response: Done.

Comment #4:

To enable readers to better appreciate research findings and to encourage full and transparent reporting of outcomes, The Lancet family journals offer to publish a webaddress in accepted paper that links to the study's protocol on the author's institutional website (see Lancet 2009; 373: 992). This is particularly encouraged for randomised controlled trials, but is welcome for all types of research.

Response: The Lipoprotein(a) Studies Collaboration is described at the webpage https://clinicalepi.i-med.ac.at/research/lpasc/.

Comment #5:

We ask all authors of, and all contributors (including medical writers and editors) to specify their conflicts of interest (if any) and individual contributions to a manuscript under consideration at The Lancet. The Lancet will not publish any articles unless we have a completed author statement form, conflict of interest form, and the signatures of all authors. Please sign and complete the author statement form (http://www.thelancet.com/for-authors/forms#author-sigs) and the ICMJE conflicts of interest statement form (http://www.thelancet.com/for-authors/forms#icmje-coi), and either upload the signed copies in to EES with your manuscript, scan and email to editorial@lancet.com. In addition, please also include written consent of any cited individual(s) noted in acknowledgments or personal communications.

The Lancet's requirements are described in more detail at the Information for Authors page at: http://www.thelancet.com/authors/lancet/authorinfo

The editors may use such information as a basis for editorial decisions and will publish such disclosures if they are believed to be important to readers in judging the manuscript. In summary, the signed statements we require are authors' contribution and signatures, signed conflict of interest statement for ALL authors, signed copyright permissions for previously published material, signed consent from individuals cited in the Acknowledgements, signed consent for use of cited personal communications, and signed patient's consent and permission to publish (if not already submitted).

Response: Done.

1 **Baseline and on-statin treatment lipoprotein(a) levels predict cardiovascular events:**
2 **An individual-patient-data meta-analysis of statin outcome trials**

3 **Brief title:** Lp(a) and CVD risk in statin outcome trials

4 Peter Willeit, Paul M. Ridker, Paul J. Nestel, John Simes, Andrew M. Tonkin, Terje R.
5 Pedersen, Gregory G. Schwartz, Anders G. Olsson, Helen M. Colhoun, Florian Kronenberg,
6 Christiane Drechsler, Christoph Wanner, Samia Mora, Anastasia Lesogor, Sotirios Tsimikas

7 Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria, and
8 Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK (P
9 Willeit MD PhD); Brigham and Women's Hospital, Harvard Medical School, Boston, MA,
10 USA (Prof P M Ridker MD, Samia Mora, MD); Baker Heart & Diabetes Institute,
11 Melbourne, Australia (Prof P J Nestel MD); NHMRC Clinical Trials Centre, University of
12 Sydney, Australia (Prof J Simes MD); Department of Epidemiology and Preventive
13 Medicine, Monash University, Melbourne, Australia (Prof A M Tonkin MD); Oslo University
14 Hospital, Ullevål and Medical Faculty, University of Oslo, Oslo, Norway (Prof T R Pederson
15 MD); Division of Cardiology, VA Medical Center and University of Colorado School of
16 Medicine, Denver, CO, USA (Prof G G Schwartz MD PhD); Department of Medicine and
17 Care, Faculty of Health Sciences, University of Linköping, Linköping, Sweden (Prof A G
18 Olsson MD PhD); MRC Human Genetics Unit, Centre for Genomic and Experimental
19 Medicine, MRC Institute of Genetics & Molecular Medicine, Edinburgh, UK (Prof H
20 Colhoun MD); Division of Genetic Epidemiology, Department of Medical Genetics,
21 Molecular and Clinical Pharmacology, Medical University of Innsbruck, Innsbruck, Austria
22 (Prof F Kronenberg MD), Division of Nephrology, Department of Internal Medicine 1 and
23 Comprehensive Heart Failure Centre, University Hospital of Würzburg, Würzburg, Germany
24 (C Drechsler MD PhD, Prof C Wanner MD); Novartis Pharma AG, Basel, Switzerland (A
25 Lesogor MD); Vascular Medicine Program, Sulpizio Cardiovascular Center, Division of
26 Cardiology, Department of Medicine, University of California San Diego, La Jolla, CA, USA
27 (Prof S Tsimikas MD)

28 **Key words:** Lipoprotein(a), cardiovascular disease, statin, outcomes, meta-analysis

29 **3458** words, **3** tables, **3** figures, **5** supplementary tables, **2** supplementary figures

30 **Correspondence to:** Associate Professor Peter Willeit MD PhD, Department of Neurology,
31 Medical University of Innsbruck, Innsbruck, Austria, phone: +43 512 504-83493; email:
32 peter.willeit@i‑med.ac.at; or Professor Sotirios Tsimikas MD, Vascular Medicine Program,
33 Sulpizio Cardiovascular Center, University of California San Diego, phone: +1 8585346109;
34 email: stsimikas@ucsd.edu.

Abstract (300 words)

Background: Elevated lipoprotein(a) [Lp(a)] is a genetic risk factor for cardiovascular disease (CVD) in general population studies, but its contribution to CVD risk in patients with established CVD or on statin therapy is uncertain.

Methods: Patient-level data from seven randomized placebo-controlled statin outcomes trials were collated and harmonized to calculate hazard ratios for CVD, defined as fatal or non-fatal coronary heart disease, stroke, or revascularisation procedures. Hazard ratios for CVD were estimated within each trial across pre-defined Lp(a) groups (15-<30, 30-<50, and ≥50 vs. <15 mg/dL), before pooling estimates using multivariate random-effects meta-analysis.

Findings: Analyses included data for 29069 patients with repeat Lp(a) measurements (mean age 62 years; 28% female; 5751 events during 95576 person-years at risk). Initiation of statin therapy reduced low-density-lipoprotein cholesterol (mean change [95% CI]: -39% [-43, -35]) without a significant change in Lp(a). Associations of baseline and on-statin treatment Lp(a) with CVD risk were approximately linear with increased risk at Lp(a) values ≥30 mg/dL for baseline Lp(a) and ≥50 mg/dL for on-statin Lp(a). Age- and sex-adjusted hazard ratios across Lp(a) groups [referent: Lp(a) <15 mg/dL] were 1·04 (0·91, 1·18), 1·11 (1·00, 1·22), and 1·31 (1·08, 1·58) for baseline Lp(a), and 0·94 (0·81, 1·10), 1·06 (0·94, 1·21), and 1·43 (1·15, 1·76) for on-statin Lp(a). Hazard ratios were virtually identical after further adjustment for prior CVD, diabetes, smoking, systolic blood pressure, low-density-lipoprotein cholesterol, and high-density-lipoprotein cholesterol. The association of on-statin Lp(a) with CVD risk was stronger than for on-placebo Lp(a) (interaction P=0·010) and was more pronounced at younger ages (interaction P=0·008) without effect modification by any other patient-level or study-level characteristics.

Interpretation: In this individual-patient meta-analysis of statin-treated patients, elevated baseline and on-statin Lp(a) showed an independent, approximately linear relationship with CVD risk. This study provides a rationale for testing the Lp(a) lowering hypothesis in CVD outcomes trials.

Funding: Novartis Pharma AG provided support for the performance of the meta-analysis.

Introduction

Lipoprotein(a) [Lp(a)] is a lipoprotein composed of apolipoprotein(a) covalently bound to apolipoprotein B (apoB) of a low-density lipoprotein (LDL) like particle.[1,2] Lp(a) mediates atherogenicity via its LDL moiety that has a similar proportion of cholesterol content as traditional LDL particles. In addition, it induces pro-inflammatory responses[3,4] via accumulation of oxidised phospholipids[5] and potentially exerts pro-thrombotic effects via the plasminogen-like apolipoprotein(a) moiety.[6] In contrast to other major lipoproteins, there is no approved specific therapy to lower circulating plasma levels of Lp(a).

Epidemiologic[7] and genetic[8,9] evidence has accumulated over the last decade showing that elevated Lp(a), driven primarily by the *LPA* gene,[10] is associated with increased risk of coronary heart disease, stroke, peripheral arterial disease, and calcific aortic valve stenosis.[1,2,11] These data have established Lp(a) as a cardiovascular disease (CVD) risk factor, but the bulk of evidence is based on studies involving individuals without prior CVD and without intensive secondary prevention therapies. In contrast, the role of elevated Lp(a) in patients with prior CVD events or on statin therapy and other guideline-recommended therapies is less clear. Prior studies in this patient population yielded inconsistent results, with findings ranging from significant positive associations to null associations such as following acute coronary syndromes (reviewed in reference[2]). In addition, several studies, including JUPITER[12] and AIM-HIGH[13], have shown that elevated Lp(a) remain predictive for CVD risk at LDL-cholesterol (LDL-C) levels <70 mg/dL,[1] but other studies suggest a positive association only when LDL-C is elevated.[14] Furthermore, a major limitation of all post hoc studies reporting Lp(a) levels and outcomes is that they involved only a small number of patients with Lp(a) values above 50 mg/dL and therefore were uniformly underpowered to test the hypothesis that elevated Lp(a) levels are associated with increased CVD risk in the setting of statin therapy or prior history of CVD.

To test this hypothesis with adequate statistical power, we established the Lipoprotein(a) Studies Collaboration, a consortium of patient-level data from placebo-controlled trials of statins with patient-level data on CVD outcomes and Lp(a) measurements at baseline and follow-up (i.e. under statin treatment). We now report the results of this analysis in documenting the associations of baseline and on-treatment Lp(a) with cardiovascular risk.

Methods

Trials included in the meta-analysis

To be eligible in the meta-analysis, randomized placebo-controlled statin trials were required to have assayed Lp(a) concentration at baseline and follow-up, have recorded incidence of CVD outcomes using well-defined criteria, and be willing to share patient data at the individual-level. We included data from AFCAPS, CARDS, 4D, JUPITER, LIPID, MIRACL, and 4S. Their study design, target population, and entry criteria are summarised in **Table 1**; more detailed descriptions of trial designs[15–21] and Lp(a) methodology and data[12,22–26] were previously reported by each trial. Trials not included in the meta-analysis were either not allowed or willing to provide individual-level patient data. Due to contractual agreements on sharing individual patient data, other eligible trials could not be included in the meta-analysis. All contributing trials have obtained ethics approval and patients' informed consent.

Statistical analyses

108 Analyses were conducted according to a pre-specified analysis plan, developed prior to any
109 combined analyses. Lp(a) values were log_e-transformed. Of 45044 patients enrolled in the
110 seven trials, 15975 (35·5%) patients were excluded because of missing Lp(a) measurements
111 at both baseline and follow-up, leaving 29069 patients for analysis (for CONSORT diagram,
112 please refer to **Supplementary Figure 1**). There were minimal differences in baseline
113 characteristics of patients with or without available Lp(a) measurements (**Supplementary
114 Table 1**). In all trials except 4S, on-statin Lp(a) during follow-up was measured at one time-
115 point. In the 4S trial, on-statin Lp(a) was estimated as the geometric mean of Lp(a) values
116 assessed at up to four distinct time points. Lp(a) values provided in nmol/L were divided by
117 2·4 (JUPITER), as previously described[27], and those provided in IU/L by 19·07 (4S) to
118 convert them to the common unit of mg/dL. When information on Lp(a) was missing either at
119 baseline (0·5%) or at follow-up (5·5%), their Lp(a) value was mean-imputed from study-
120 specific mixed-effects models which predicted Lp(a) values using fixed effects for assigned
121 treatment, time-in-study, and the interaction of the two variables, plus a random intercept
122 allowed to vary at the patient level.

123 Because conventional "LDL-C" assays capture cholesterol both in LDL and Lp(a) particles,
124 LDL-C values were corrected for the latter. Lp(a) mass in mg/dL is composed of ~30-45%
125 cholesterol.[28] We used a conservative measurement of the content of Lp(a)-C by multiplying
126 Lp(a) mass (in mg/dL) by 0·30 to derive Lp(a)-cholesterol, and then subtracting this value
127 from the measured LDL-C to obtain corrected LDL-C (LDL-C$_{corr}$).[28]

128 The combined CVD endpoint was defined as the occurrence of fatal or non-fatal coronary
129 heart disease, stroke, or any coronary or carotid revascularisation procedures. In analysing
130 on-treatment Lp(a), all CVD events that occurred after randomisation were considered
131 because any change in Lp(a) under statin therapy is anticipated to occur within a short time
132 period (sensitivity analyses omitted the initial period of follow-up).[12]

133 Associations of Lp(a) with CVD risk were estimated using a two-step approach, with
134 estimates calculated within each study separately before pooling them across studies using
135 multivariate random-effects meta-analysis.[29] Hazard ratios were calculated using Cox
136 proportional hazard regression models which used time-on-study as a timescale, were
137 stratified by trial arm, and compared the pre-specified Lp(a) groups <15 mg/dL, 15-<30
138 mg/dL, 30-<50 mg/dL, and ≥50 mg/dL. The assumption for the proportionality of hazards
139 was tested using Schoenfeld residuals and was met. The analysis had four inter-related
140 principal aims. First, to evaluate shapes of associations, pooled hazard ratios were calculated
141 over Lp(a) groups and plotted against the pooled geometric mean of Lp(a) concentration
142 within each category.[29] Second, to determine the extent of confounding, hazard ratios were
143 progressively adjusted for age, sex, prior CVD, diabetes, smoking, systolic blood pressure,
144 LDL-C$_{corr}$, and high-density-lipoprotein-cholesterol ("multivariable adjusted model"). Further
145 adjustment for body-mass index and estimated glomerular filtration rate was employed in the
146 subset of patients, in which these data were available. Third, to investigate whether the
147 predictive value of follow-up Lp(a) differed between patients randomized to statin vs.
148 placebo, interaction models by trial arm were fitted. Fourth, to investigate effect modification
149 by individual-patient and study-level characteristics, formal tests of interaction and meta-
150 regression analyses with these variables were performed. There was little variability within
151 each trial of the proportion of patients with prior CVD and with a history of diabetes at
152 baseline (e.g. secondary vs. primary CVD prevention trials, diabetes as inclusion or exclusion
153 criterion) and hence effect modification by these characteristics was investigated at the study-
154 level instead of at the patient-level. Between-trial heterogeneity was assessed with the I^2

155 statistic.[30] Analyses were performed using Stata (version 14·1 MP) and involved two-sided
156 statistical tests and 95% confidence intervals. Principal analyses used a significance level of
157 P<0·05 and subgroup analyses a Bonferroni-corrected significance level of P<0·007 (for
158 seven subgroups).

Role of funding source

160 The funders of the study had no role in study design, data collection, data analysis, data
161 interpretation, or writing of the report. PW and ST had full access to all the data in the study
162 and had final responsibility for the decision to submit for publication.

Results

Summary of available data

165 Data on 29069 patients from seven contributing trials were analysed (**Table 2**). At trial entry,
166 mean age was 62 years (SD 8), 8064 were female (28%), 15252 had prior CVD (52%), 5177
167 had diabetes (18%), 4847 were current smokers (17%), mean systolic blood pressure was 137
168 mmHg (SD 18), and mean LDL-C$_{corr}$ was 3·30 mmol/L (SD 0·67). Median concentration of
169 Lp(a) at baseline was in low normal range of 11 mg/dL (interquartile range: 5-29). In cross-
170 sectional analyses, baseline Lp(a) concentration was higher in females (+12% [3, 21]), lower
171 in patients with diabetes (-17% [-24, -9]) and unrelated to smoking (+2% [-3, 8]).
172 Furthermore, LDL-C$_{corr}$, log$_e$ triglycerides, body-mass index, and systolic blood pressure
173 were associated with a lower and HDL-C with a higher Lp(a) concentration (age-and sex-
174 adjusted differences in Lp(a) per SD: -16% [-23, -8], -12% [-15, -9], -7% [-10, -5], -2% [-5, -
175 0], and +7% [3, 11]). Baseline Lp(a) was not associated with age (-1% [-2, 1] per SD).

176 A total of 14536 patients were randomized to receive statin therapy (**Table 2**). Initiation of
177 statin therapy reduced LDL-C$_{corr}$ by -39% (95% confidence interval: -43, -35). The effect of
178 statin on Lp(a) concentration was heterogeneous across trials; the pooled percentage change
179 was -0·4% (-7, 7), with three trials showing a mean increase (range +2 to +15%) and four
180 trials showing a mean decrease (range -1 to -13%) in Lp(a). The median concentration of
181 Lp(a) on statin therapy was 11 mg/dL (interquartile range: 5-32). The age- and sex-adjusted
182 correlation between baseline and follow-up log$_e$ Lp(a) was comparable in the statin arm and
183 the placebo arm (r=0.948 vs. 0.952).

Associations of baseline and on-statin Lp(a) with cardiovascular disease risk

185 During 95576 person-years at risk (median follow-up 3·0 years [interquartile range: 1·5-
186 5·3]), a total of 5751 CVD events were recorded, of which 2603 occurred in the statin arm
187 (**Table 2**). When patients were grouped by Lp(a) concentration into the categories <15
188 mg/dL, 15-<30 mg/dL, 30-<50 mg/dL, and ≥50 mg/dL, incidence rates for CVD (95% CI)
189 per 1000 person-years were as follows: 55·3 (53·4-57·3), 56·3 (52·6-60·2), 66·7 (62·0-71·8),
190 and 80·0 (75·3-84·9) for baseline Lp(a), and 49·0 (46·5-51·6), 46·4 (41·6-51·7), 56·2 (50·3-
191 62·8), and 77·2 (71·1-83·8) for on-statin Lp(a).

192 In analyses adjusted for age and sex only, associations of baseline and on-statin Lp(a) values
193 with the risk of CVD were of positive approximately linear shape, with a possible threshold
194 effect in the group with Lp(a) values of 50 mg/dL or more (**Figure 1**). For baseline Lp(a), the
195 hazard ratios compared to patients with Lp(a) values of <15 mg/dL were 1·04 (0·91, 1·18)
196 with Lp(a) values 15-<30 mg/dL, 1·11 (1·00, 1·22) with Lp(a) values 30-<50 mg/dL, and

197   1·31 (1·08, 1·58) with Lp(a) values ≥50 mg/dL (**Table 3**). For on-statin Lp(a), corresponding
198   hazard ratios were 0·94 (0·81, 1·10), 1·06 (0·94, 1·21), and 1·43 (1·15, 1·76).

199   Associations remained robust to additional adjustment for prior CVD, diabetes, smoking,
200   systolic blood pressure, LDL-C$_{corr}$, and HDL-C concentration (**Figure 1** and **Table 3**).
201   Corresponding hazard ratios were 1·04 (0·91, 1·20), 1·13 (1·02, 1·25), and 1·35 (1·11, 1·66)
202   for baseline Lp(a) and 0·95 (0·82, 1·11), 1·08 (0·95, 1·23), and 1·42 (1·16, 1·74) for on-
203   statin Lp(a). In a sensitivity analysis of patients with information on triglycerides, body-mass
204   index, or estimated glomerular filtration rate, further adjustment for these parameters did not
205   materially change the magnitude of association between Lp(a) measurements and CVD risk
206   (**Supplementary Table 2**). Effect sizes comparable with those in the principal analysis were
207   observed when further categorising the highest Lp(a) group into patients with levels 50-<75
208   mg/dL and ≥75 mg/dL (**Supplementary Table 3**) and in the on-statin analysis when omitting
209   events that occurred in the initial period between randomization and on-statin measurement
210   of Lp(a) (**Supplementary Table 4**). Trial-specific findings are provided in **Supplementary**
211   **Table 5**.

212   **Comparative predictive value of on-statin vs. on-placebo Lp(a)**

213   Lp(a) concentration measured during follow-up was more strongly associated with CVD risk
214   in the on-statin arm than in the on-placebo arm (**Figure 2**). In comparison of patients with
215   Lp(a) ≥50 mg/dL with those having Lp(a) <50 mg/dL, the age- and sex-adjusted hazard ratios
216   for CVD were 1·48 (1·23 to 1·78) for on-statin Lp(a) and 1·23 (1·04 to 1·45) for on-placebo
217   Lp(a) (interaction P=0·010). The corresponding multivariable adjusted hazard ratios were
218   1·47 (1·25 to 1·73) and 1·26 (1·06 to 1·50) (interaction P=0·031). The median time from
219   randomization to Lp(a) repeat was 1.0 years in both trial arms.

220   **Associations according to patient-level and study-level characteristics**

221   There was some heterogeneity between trials in hazard ratios for CVD, most pronounced in
222   the group with a Lp(a) concentrations ≥50 mg/dL. For example, in this group, I^2 values of
223   age- and sex-adjusted hazard ratios were 73% (43, 88) for baseline Lp(a) and 62% (13, 83)
224   for on-statin Lp(a) (**Table 3**). Apart from stronger associations of on-statin Lp(a) with CVD
225   risk at younger age (<60 years vs. 60-<70 years vs. ≥70 years; interaction P=0·008), hazard
226   ratios did not vary significantly across clinically relevant subgroups, such as by sex, smoking,
227   systolic blood pressure, lipid parameters, or body-mass index (**Figure 3**). Furthermore, the
228   magnitude of association was independent of a study's proportion of patients with prior CVD
229   or diabetes, the length of follow-up for clinical events, and the time between study baseline
230   and follow-up on-statin Lp(a) measurement (**Supplementary Figure 2**). Contributing trials
231   employed differing statin interventions, precluding a subgroup analysis by statin type or
232   statin dosage.

233   # Discussion

234   This well-powered meta-analysis of Lp(a) and CVD events reveals that patients with elevated
235   Lp(a) on statin therapy, primarily with levels of >50 mg/dL, are at a significantly higher risk
236   of CVD. The association with CVD risk was independent of conventional CVD risk factors,
237   as also reflected in the very weak or null cross-sectional correlations of Lp(a) with these risk
238   factors. Importantly, hazard ratios for high Lp(a) at baseline and under statin therapy were of
239   similar magnitude, reflecting that statin therapy may not appreciably affect Lp(a)-mediated
240   risk in patients with elevated Lp(a). Overall, these data suggest that patients with elevated

Lp(a), representing ~25% of subjects with prior CVD or statin indication,[1] are at substantial residual risk even under statin therapy. In this patient population, therapies which specifically lower Lp(a) might mitigate Lp(a)-mediated risk. An appropriately designed CVD outcomes trial with robust Lp(a)-lowering is therefore justified to test the hypothesis that lowering Lp(a) reduces CVD events, independent of statin treatment.

At baseline, Lp(a) levels were weakly associated with demographic and laboratory variables. The most significant but nevertheless weak correlations were inverse with diabetes mellitus and triglycerides. The observation of an inverse association of Lp(a) with incident diabetes has been made previously,[31] and is most pronounced at very low levels of Lp(a) (≤5 mg/dL), which are present in the 10th percentile of the global population.[1,2] It has not been determined if the findings are causal or if there is confounding by reverse causality.[32] Although the underlying mechanisms are not well understood, fasting and post-prandial insulin levels are inversely associated with Lp(a).[33] Lp(a) was weakly correlated with LDL-C, but this relationship became inversely associated after subtracting the estimated cholesterol content in Lp(a) from the laboratory measurement called "LDL-C".[28]

Prior studies evaluating the role of Lp(a) in predicting CVD in patients without CVD, using Lp(a) assays in the modern era that lack limitations of prior assays, have been almost uniformly positive.[7] However, studies in patients with prior CVD or on statin therapy have been mixed, or have suggested the effect is present primarily in patients with elevated LDL-C (reviewed in Tsimikas et al.[2]). A major limitation of all substudies reporting Lp(a) and outcomes has been power. All studies have enrolled patients with Lp(a) levels in the mid to low normal range (10-15 mg/dL, normal <30 mg/dL), as confirmed in the current meta-analysis, thus statistical power to evaluate risk in patients with highly elevated Lp(a) (i.e. >50 mg/dL) was limited. The current study is highly powered with 5751 total events and 2603 events in the statin arms, making it equivalent to, or larger than, most individual randomised controlled cardiovascular outcome trials in the modern era. In contrast to a previous analysis of individual-patient data by O'Donoghue et al,[34] our study afforded higher statistical power because it involved >10 times more CVD events, and hence was able to characterise associations with high Lp(a) concentrations more precisely. Moreover, the present analysis used clinically-relevant Lp(a) categories informed by guideline recommendations, as opposed to trial-specific quintiles.

The current meta-analysis is also highly representative of clinical care in patients treated with statins. First, these studies represent patients who were treated with moderate-high doses of the five major statins used clinically. Second, they reflect the variety of patients treated clinically, including primary prevention, high-risk primary prevention with elevated C-reactive protein or diabetes, secondary prevention, stable coronary artery disease, acute coronary syndromes, patients on dialysis and highly elevated LDL-C in the familial hypercholesterolemia range. Therefore, they broadly reflect patients with high residual risk despite statin treatment, potentially due to other, unmodified risk factors such as elevated Lp(a).

The risk thresholds chosen reflect clinical risk as suggested by epidemiologic and genetic studies. The reference cutoff of <15 mg/dL, reflects roughly the median global level of Lp(a).[35,36] Lp(a) <30 mg/dL represents the usual cutoff in US laboratories that is considered as normal level, and is based on data showing that risk of myocardial infarction starts to accrue at levels above 25-30 mg/dL.[7,37] The range of 30-50 mg/dL was chosen as this is the grey zone between what is considered pathophysiologically relevant and >50 mg/dL is based

287   on what the European Atherosclerosis Society as considered elevated levels at highest risk
288   based on the European population prevalence of 20%.

289   In this study, elevation of CVD risk became evident at baseline Lp(a) 30 to <50 mg/dL and
290   was further pronounced when Lp(a) levels exceeded 50 mg/dL, including patients treated
291   with statins. The hazard ratios for Lp(a) ≥50 mg/dL are consistent with recent PCSK9
292   inhibitor studies in patients with background statin therapy.[38] Additional analyses at even
293   higher Lp(a), i.e. ≥75 mg/dL were limited by low power due to small numbers of patients
294   with Lp(a) levels in this range, but support a graded relationship of Lp(a) with cardiovascular
295   risk. Outcome trials of Lp(a) lowering are likely to include patients with mean baseline Lp(a)
296   substantially >50 mg/dL, therefore, extrapolation to event reduction with Lp(a) lowering
297   from these data may be an underestimate.

298   A key observation of this study is that on-statin Lp(a) was more strongly associated with
299   CVD risk than on-placebo Lp(a). A small angiographic study initially suggested that the risk
300   of Lp(a) is attenuated when LDL-C is well controlled.[39] In contrast, the current study,
301   utilising a far larger body of data, supports the opposite conclusion that risk is independently
302   associated with both LDL-C and Lp(a). When LDL-attributable risk is reduced with statin
303   treatment, Lp(a)-associated risk becomes an even stronger predictor of residual risk. This
304   observation is particularly evident at Lp(a) levels exceeding 50 mg/dL. In support of our
305   observation in this study, the trials FOURIER (European Atherosclerosis Society, May 2018)
306   and ODYSSEY OUTCOMES (International Atherosclerosis Society, June 2018) have
307   recently presented preliminary findings of their data, both showing that elevated baseline
308   Lp(a) remains a risk factor even with on-treatment LDL-C <50 mg/dL in patients treated with
309   statins and PCSK9 inhibitors. The findings raise the importance of determining whether there
310   is a cardiovascular benefit of treatment to reduce Lp(a) when initial levels exceed this
311   threshold, irrespective of concurrent treatment with statin. A second important observation is
312   that all major subgroups of patients seemed to be at risk of elevated Lp(a), including those
313   >70 years old, females, smokers, those with low and high LDL-C$_{corr}$, low HDL-C and all
314   categories of body-mass index.

315   It is important to emphasize that the Lp(a) hypothesis remains to be tested. To do so requires
316   a randomized trial that compares cardiovascular outcomes in patients treated with an agent
317   that specifically lowers Lp(a) versus placebo. Such a trial may be possible with antisense
318   oligonucleotide targeting *LPA* messenger RNA, thereby reducing plasma Lp(a) levels. Phase
319   I and II trials with this agent have shown the potential to lower Lp(a) levels by over 90%
320   without major effects on other classes of lipoproteins.[27,40]

321   One limitation of this study is that individual-patient data could not be obtained from several
322   other statin trials that reported Lp(a) levels and outcomes. It is possible that inclusion of other
323   data would have modified the observed effect sizes. Secondly, the relationship of Lp(a) to
324   residual cardiovascular risk under treatment with non-statin lipid-modifying agents (e.g.,
325   ezetimibe, PCSK9 inhibitors) remains undetermined. Third, the Lp(a) assays were
326   heterogeneous and most were in Lp(a) mass rather than in Lp(a) molar concentration and the
327   timepoints at which they were measured in each trial were not uniform. Therefore, the assays
328   not reported in mg/dL had to be mathematically converted to mg/dL, which may have
329   introduced imprecision into the Lp(a) measurement. A recent NHLBI Working Group on
330   Lp(a) recommended global standardization of Lp(a) assays to address this limitation.[2] Fourth,
331   we cannot rule out that index event bias may have attenuated effect sizes in secondary
332   prevention trials, although the scope of this bias was reduced by employment of multivariable
333   adjustment. Fifth, our analysis identified moderate to high between-study heterogeneity,

334 which could not be explained by baseline disease status (i.e. prior CVD or prior diabetes) nor
335 by differing lengths of follow-up periods. Finally, the data for the change in Lp(a) post statin
336 therapy was heterogeneous across studies, with both increases and decreases, but no net
337 change. Due to different assays used in each of the trials, and the need for conversion of all
338 data to mg/dL, and the higher precision required to show intra-individual changes, these data
339 should be considered hypothesis generating. A more robust test of this particular hypothesis
340 should ideally be performed using the same assay.

341 In conclusion, this meta-analysis demonstrates an approximately linear relationship of
342 cardiovascular risk to levels of Lp(a), evident at Lp(a) levels 30-50 mg/dL, pronounced at
343 levels ≥50 mg/dL, and persisting despite statin treatment. These data provide a rationale for
344 evaluating drugs that can specifically lower Lp(a) and might have the potential to reduce
345 residual cardiovascular risk independent of statin treatment.

Contributors

347 PW and ST wrote the analysis plan, collected and harmonized the data, and wrote the first
348 draft of the manuscript. PW and ST had access to all the raw data and PW performed the
349 statistical analysis. PMR, PJN, JS, AMT, TRP, GGS, AGO, HMC, FK, CD, CW, and SM
350 have collected patient data in statin trials and provided cleaned data to the coordinating
351 centre. All authors provided contributed to writing the final report and approved the version
352 to be submitted to the journal.

Declaration of interests

354 PW reports consultancy fees from Novartis Pharmaceuticals during the conduct of the study,
355 and travel expenses from Bayer, Daiichi Sankyo, and Sanofi-Aventis outside the submitted
356 work. PMR reports grants from AstraZeneca during the conduct of the study, grants from
357 Novartis, Kowa, Pfizer, and NHLBI outside of the submitted work, and personal fees from
358 Novartis, Sanofi outside of the submitted work. AMT reports personal fees from Amgen,
359 personal fees and non-financial support from Bayer, personal fees from Merck, personal fees
360 from Pfizer outside the submitted work. TRP reports personal fees from Amgen and from
361 Sanofi Regeneron outside the submitted work. GGS reports grants from Pfizer during the
362 conduct of the study, and grants from Cerenis, Roche, Sanofi, and The Medicines Company
363 outside the submitted work. HMC reports grants from Astra Zeneca, Boehringer Ingelheim,
364 being a shareholder at Bayer, grants, personal fees, non-financial support and travel expenses
365 from Eli Lilly & company, institutional fees from Novartis Pharmaceuticals, grants, non-
366 financial support and travel expenses from Regeneron, grants and speaker fees from Pfizer
367 Inc, grants from and being a shareholder at Roche Pharmaceuticals, grants and travel
368 expenses from Sanofi Aventis, honorarium and speakers bureau from Sanofi, grants and
369 travel expenses from Novo Nordisk during the conduct of the study. CW reports personal
370 fees from Boehringer Ingelheim and from Sanofi-Genzyme outside the submitted work. SM
371 reports institutional support from NIH grants R01 HL117861, R01 HL134811, K24
372 HL136852, non-financial support from Quest Diagnostics for measuring Lp(a) in JUPITER,
373 and personal fees from Quest Diagnostics and institutional research grant from Atherotech
374 Diagnostics outside the submitted work. The JUPITER trial was funded by AstraZeneca. AL
375 is an employee of Novartis Pharma AG. ST has research support from the Fondation Leducq
376 and NIH grants R01-HL119828, R01-HL078610, R01 HL106579, R01 HL128550, R01
377 HL136098, P01 HL136275 and R35 HL135737, currently has a dual appointment at the

References

1 Tsimikas S. A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies. *J Am Coll Cardiol* 2017; **69:** 692–711.

2 Tsimikas S, Fazio S, Ferdinand KC, et al. NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis. *J Am Coll Cardiol* 2018; **71:** 177–92.

3 van der Valk FM, Bekkering S, Kroon J, et al. Oxidized Phospholipids on Lipoprotein(a) Elicit Arterial Wall Inflammation and an Inflammatory Monocyte Response in Humans. *Circulation* 2016; **134:** 611–24.

4 Wiesner P, Tafelmeier M, Chittka D, et al. MCP-1 binds to oxidized LDL and is carried by lipoprotein(a) in human plasma. *J Lipid Res* 2013; **54:** 1877–83.

5 Leibundgut G, Scipione C, Yin H, et al. Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a). *J. Lipid Res.* 2013; **54:** 2815–30.

6 Boffa MB, Koschinsky ML. Lipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease? *J Lipid Res* 2016; **57:** 745–57.

7 Emerging Risk Factors Collaboration. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. *JAMA* 2009; **302:** 412–23.

8 Clarke R, Peden JF, Hopewell JC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. *N Engl J Med* 2009; **361:** 2518–28.

9 Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. *JAMA* 2009; **301:** 2331–39.

10 Schmidt K, Noureen A, Kronenberg F, Utermann G. Structure, function, and genetics of lipoprotein (a). *J Lipid Res* 2016; **57:** 1339–59.

11 Thanassoulis G, Campbell CY, Owens DS, et al. Genetic associations with valvular calcification and aortic stenosis. *N Engl J Med* 2013; **368:** 503–12.

12 Khera AV, Everett BM, Caulfield MP, et al. Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). *Circulation* 2014; **129:** 635–42.

13 Albers JJ, Slee A, O'Brien KD, et al. Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes. The AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes). *J Am Coll Cardiol* 2013; **62:** 1575–79.

14 O'Donoghue ML, Morrow DA, Tsimikas S, et al. Lipoprotein(a) for risk assessment in patients with established coronary artery disease. *J Am Coll Cardiol* 2014; **63:** 520–27.

422 15 Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with
423   lovastatin in men and women with average cholesterol levels: results of
424   AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. *JAMA*
425   1998; **279:** 1615–22.
426 16 Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular
427   disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes
428   Study (CARDS): multicentre randomised placebo-controlled trial. *Lancet* 2004; **364:**
429   685–96.
430 17 Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in
431   men and women with elevated C-reactive protein. *N Engl J Med* 2008; **359:** 2195–207.
432 18 Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group.
433   Prevention of cardiovascular events and death with pravastatin in patients with coronary
434   heart disease and a broad range of initial cholesterol levels. *N Engl J Med* 1998; **339:**
435   1349–57.
436 19 Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent
437   ischemic events in acute coronary syndromes: the MIRACL study: a randomized
438   controlled trial. *JAMA* 2001; **285:** 1711–18.
439 20 Scandinavian Simvastatin Survival Study. Randomised trial of cholesterol lowering in
440   4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study
441   (4S). *Lancet* 1994; **344:** 1383–89.
442 21 Krane V, Schmidt K-R, Gutjahr-Lengsfeld LJ, et al. Long-term effects following 4 years
443   of randomized treatment with atorvastatin in patients with type 2 diabetes mellitus on
444   hemodialysis. *Kidney Int* 2016; **89:** 1380–87.
445 22 Deshmukh HA, Colhoun HM, Johnson T, et al. Genome-wide association study of genetic
446   determinants of LDL-c response to atorvastatin therapy: importance of Lp(a). *J Lipid Res*
447   2012; **53:** 1000–11.
448 23 Kollerits B, Drechsler C, Krane V, et al. Lipoprotein(a) concentrations, apolipoprotein(a)
449   isoforms and clinical endpoints in haemodialysis patients with type 2 diabetes mellitus:
450   results from the 4D Study. *Nephrol Dial Transplant* 2016; **31:** 1901–08.
451 24 Nestel PJ, Barnes EH, Tonkin AM, et al. Plasma lipoprotein(a) concentration predicts
452   future coronary and cardiovascular events in patients with stable coronary heart disease.
453   *Arterioscler Thromb Vasc Biol* 2013; **33:** 2902–08.
454 25 Tsimikas S, Witztum JL, Miller ER, et al. High-dose atorvastatin reduces total plasma
455   levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100
456   in patients with acute coronary syndromes in the MIRACL trial. *Circulation* 2004; **110:**
457   1406–12.
458 26 Berg K, Dahlén G, Christophersen B, Cook T, Kjekshus J, Pedersen T. Lp(a) lipoprotein
459   level predicts survival and major coronary events in the Scandinavian Simvastatin
460   Survival Study. *Clin Genet* 1997; **52:** 254–61.
461 27 Tsimikas S, Viney NJ, Hughes SG, et al. Antisense therapy targeting apolipoprotein(a): a
462   randomised, double-blind, placebo-controlled phase 1 study. *Lancet* 2015; **386:** 1472–83.
463 28 Yeang C, Witztum JL, Tsimikas S. 'LDL-C' = LDL-C + Lp(a)-C: implications of
464   achieved ultra-low LDL-C levels in the proprotein convertase subtilisin/kexin type 9 era
465   of potent LDL-C lowering. *Curr Opin Lipidol* 2015; **26:** 169–78.
466 29 Thompson S, Kaptoge S, White I, et al. Statistical methods for the time-to-event analysis
467   of individual participant data from multiple epidemiological studies. *Int. J. Epidemiol.*
468   2010; **39:** 1345–59.
469 30 Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med*
470   2002; **21:** 1539–58.

471   31 Paige E, Masconi KL, Tsimikas S, et al. Lipoprotein(a) and incident type-2 diabetes:
472   results from the prospective Bruneck study and a meta-analysis of published literature.
473   *Cardiovasc Diabetol* 2017; **16:** 38.
474   32 Tsimikas S. In Search of a Physiological Function of Lp(a): Causality of Elevated Lp(a)
475   levels and Reduced Incidence of Type-2 Diabetes Mellitus. *J Lipid Res* 2018.
476   33 Rainwater DL, Haffner SM. Insulin and 2-hour glucose levels are inversely related to
477   Lp(a) concentrations controlled for LPA genotype. *Arterioscler Thromb Vasc Biol* 1998;
478   **18:** 1335–41.
479   34 O'Donoghue ML, Morrow DA, Tsimikas S, et al. Lipoprotein(a) for risk assessment in
480   patients with established coronary artery disease. *Journal of the American College of
481   Cardiology* 2014; **63:** 520–27.
482   35 Varvel S, McConnell JP, Tsimikas S. Prevalence of Elevated Lp(a) Mass Levels and
483   Patient Thresholds in 532 359 Patients in the United States. *Arterioscler Thromb Vasc
484   Biol* 2016; **36:** 2239–45.
485   36 Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a cardiovascular risk
486   factor: current status. *Eur Heart J* 2010; **31:** 2844–53.
487   37 Kostner GM, Avogaro P, Cazzolato G, Marth E, Bittolo-Bon G, Qunici GB. Lipoprotein
488   Lp(a) and the risk for myocardial infarction. *Atherosclerosis* 1981; **38:** 51–61.
489   38 Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and Clinical Outcomes in
490   Patients with Cardiovascular Disease. *N Engl J Med* 2017; **376:** 1713–22.
491   39 Maher VM, Brown BG, Marcovina SM, Hillger LA, Zhao XQ, Albers JJ. Effects of
492   lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a). *JAMA*
493   1995; **274:** 1771–74.
494   40 Viney NJ, van Capelleveen JC, Geary RS, et al. Antisense oligonucleotides targeting
495   apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind,
496   placebo-controlled, dose-ranging trials. *Lancet* 2016; **388:** 2239–53.
497

Research in context

498

Evidence before this study: Lp(a) has been associated with increased risk of incident cardiovascular disease in primary care populations, but its role in predicting cardiovascular events in high-risk patients treated with statins is unclear. We searched PubMed for relevant clinical trials published up to July 9, 2018, using the search terms "Lipoprotein(a)" or "Lp(a)", plus "statin" and "cardiovascular diseases"[MeSH]. Our review identified seven statin trials (4D, 4S, FLARE, JUPITER, LIPID, MIRACL, and TNT), which reported on the association of Lp(a) with cardiovascular risk. The interpretation of the available evidence is complicated by inconsistent findings across trials (positive vs. null associations), limited statistical power of single trials, limited availability of follow-up Lp(a) measurements, and differing definitions of Lp(a) categories across trials.

Added value of this study: We obtained patient-level data in seven placebo-controlled statin trials encompassing 29069 patients and analysed the relationship of baseline and on-treatment Lp(a) to risk of major adverse cardiovascular events. Elevated Lp(a) of 50 mg/dL or higher, at baseline or on-treatment, was associated with an increased hazard ratio of cardiovascular events independent of other cardiovascular risk factors and evident on treatment with either statin or placebo.

Implications of all the available evidence: These data suggest that residual risk is present in patients with elevated Lp(a) that is not addressed by statins and supports the rationale for outcomes trials to test specific therapies to lower Lp(a).

Tables

520

Table 1 – Design features of contributing trials.

Cohort	Years of baseline	Target population	Lipid entry criteria, mmol/L	Comparator to placebo	CVD outcome definition				
					MI	Stable angina	Stroke	Revascularisation	Other
AFCAPS[15]	1990-1993	Primary prevention	TC 4·65-6·82, LDL-C 3·36-4·91, TG ≤4·52, HDL-C ≤1·16♂ and ≤1·22♀	Lovastatin 20mg	●	●	●	●	●*
CARDS[22]	1997-2001	Type 2 diabetes	LDL-C ≤4·14, TG ≤6·78	Atorvastatin 10mg	●	○	●	●	○
4D[23]	1998-2002	Type 2 diabetes + hemodialysis	LDL-C 2·07-4·92, TG ≤11·3	Atorvastatin 20mg	●	○	●	●	○
JUPITER[12]	2003-2006	Primary prevention with C-reactive protein >2mg/dL	LDL-C <3·4, TG <5·65	Rosuvastatin 20mg	●	○	●	●	●†
LIPID[24]	1990-1992	Prior myocardial infarction or unstable angina	TC 4·0-7·0, TG <5·0	Pravastatin 40mg	●	○	●	●	○
MIRACL[25]	1997-1999	Acute coronary syndrome	TC <7·0	Atorvastatin 80mg	●	○	●	●	○
4S[26]	1989-1990	Prior myocardial infarction or angina	TC 5·5-8·0, TG ≤2·5	Simvastatin 20mg	●	○	○	●	○

AFCAPS=Air Force/Texas Coronary Atherosclerosis Prevention Study. CARDS=Collaborative Atorvastatin Diabetes Study. CVD=cardiovascular disease. 4D=Die Deutsche Diabetes-Dialyse-Studie. HDL-C=high-density lipoprotein cholesterol. JUPITER=Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin. LDL-C=low-density lipoprotein cholesterol. LIPID=Long-Term Intervention with Pravastatin in Ischaemic Disease. MI=myocardial infarction. MIRACL=Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering. 4S=Scandinavian Simvastatin Survival Study. TC=total cholesterol. TG=triglycerides. *Transient ischemic attack, peripheral vascular disease, sudden death, and deaths from other cardiovascular causes. †Deaths from other cardiovascular causes.

529

Table 2 – Patient characteristics.

|	AFCAPS	CARDS	4D	JUPITER	LIPID	MIRACL	4S	Total
Baseline								
No. of patients	1005	2470	1249	9612	7863	2431	4439	29069
Lp(a), mg/dL, median (IQR)	7 (3-17)	9 (5-22)	12 (5-42)	11 (5-23)	14 (7-44)	10 (5-29)	10 (4-28)	11 (5-29)
<15 mg/dL	733 (73)	1658 (67)	709 (57)	5896 (61)	4118 (52)	1481 (61)	2654 (60)	17249 (59)
15-<30 mg/dL	134 (13)	310 (13)	129 (10)	1867 (19)	1147 (15)	362 (15)	781 (18)	4730 (16)
30-<50 mg/dL	84 (8)	212 (9)	140 (11)	851 (9)	877 (11)	223 (9)	714 (16)	3101 (11)
≥50 mg/dL	54 (5)	290 (12)	271 (22)	998 (10)	1721 (22)	365 (15)	290 (7)	3989 (14)
Age, yrs	59 (7)	62 (8)	66 (8)	66 (8)	61 (8)	65 (11)	59 (7)	62 (8)
Female sex	173 (17)	779 (32)	576 (46)	3556 (37)	1333 (17)	820 (34)	827 (19)	8064 (28)
Prior CVD	0 (0)	6 (0)	513 (41)	0 (0)	7863 (100)	2431 (100)	4439 (100)	15252 (52)
Diabetes	32 (3)	2470 (100)	1249 (100)	0 (0)	676 (9)	548 (23)	202 (5)	5177 (18)
Current smoking	130 (13)	551 (22)	108 (9)	1492 (16)	735 (9)	693 (29)	1138 (26)	4847 (17)
SBP, mmHg	136 (17)	144 (16)	146 (22)	136 (17)	134 (19)	128 (20)	139 (20)	137 (18)
LDL-C$_{corr}$, mmol/L	–	2·75 (0·78)	3·00 (0·86)	2·57 (0·49)	3·68 (0·74)	3·04 (0·86)	4·74 (0·66)	3·30 (0·67)
HDL-C, mmol/L	–	1·64 (0·50)	0·94 (0·34)	1·35 (0·40)	0·96 (0·24)	1·20 (0·31)	1·19 (0·30)	1·21 (0·35)
BMI, kg/m²	26 (3)	29 (4)	28 (5)	29 (6)	–	28 (5)	26 (3)	28 (5)
eGFR, mL/min	–	–	–	75 (17)	71 (17)	–	–	73 (17)
Apo-B, g/L	–	1·16 (0·24)	1·10 (0·30)	1·08 (0·21)	1·33 (0·25)	–	1·16 (0·18)	1·17 (0·23)
On-statin								
No. of patients	504	1255	616	4802	3941	1200	2218	14536
Time to Lp(a) repeat, yrs, median	1·0	2·5	0·5	1·0	1·0	0·2	2·5	1·0
Lp(a), mg/dL, median (IQR)	7 (3-19)	8 (4-22)	11 (5-40)	11 (4-25)	13 (6-43)	11 (5-33)	11 (4-33)	11 (5-32)
<15 mg/dL	366 (73)	864 (69)	351 (57)	2912 (61)	2106 (53)	707 (59)	1268 (57)	8574 (59)
15-<30 mg/dL	59 (12)	134 (11)	60 (10)	868 (18)	548 (14)	175 (15)	321 (15)	2165 (15)
30-<50 mg/dL	43 (9)	103 (8)	73 (12)	417 (9)	439 (11)	96 (8)	375 (17)	1546 (11)
≥50 mg/dL	36 (7)	154 (12)	132 (21)	605 (13)	848 (22)	222 (19)	254 (12)	2251 (15)
% change vs. baseline (95% CI)	-1% (-6, 4)	-13% (-15, -10)	-6% (-9, -3)	2% (1, 3)	-7% (-8, -5)	9% (6, 12)	15% (13, 17)	-0·4% (-7, 7)
LDL-C$_{corr}$, mmol/L	–	1·68 (0·58)	1·73 (0·78)	1·43 (0·70)	2·57 (0·71)	1·56 (0·77)	2·97 (0·70)	1·99 (0·70)
% change vs. baseline (95% CI)	–	-37% (-38, -36)	-41% (-43, -39)	-43% (-44, -42)	-29% (-30, -29)	-47% (-49, -46)	-37% (-37, -36)	-39% (-43, -35)
CVD incidence								
Follow-up, yrs, median (IQR)	5·6 (4·8-6·2)	4·1 (3·1-4·8)	2·4 (1·4-3·7)	2·0 (1·5-2·4)	5·4 (3·1-6·0)	0·3 (0·3-0·3)	5·3 (3·9-5·5)	3·0 (1·5-5·3)
No. of events, overall	68	170	338	234	3040	537	1364	5751
No. of events, statin arm	31	71	166	81	1428	258	568	2603

Mean (SD) or n (%), unless stated otherwise. Percentages may not sum up to 100% due to rounding. For full trial names, refer to footnote of Table 1. Total means (standard deviations) and % changes (95% confidence intervals) were calculated by pooling study-specific estimates with random-effects meta-analysis. Apo-B=apolipoprotein B. BMI=body-mass index. CVD=cardiovascular disease. eGFR=estimated glomerular filtration rate. HDL-C=high-density lipoprotein cholesterol. IQR=interquartile-range. LDL-C$_{corr}$=low-density lipoprotein cholesterol corrected for Lp(a)-cholesterol. SBP=systolic blood pressure.

Table 3 – Associations of baseline and on-statin Lp(a) with incident cardiovascular disease according to different levels of adjustment.

Lp(a) measurement / adjustment	Lp(a) 15-<30 mg/dL			Lp(a) 30-<50 mg/dL			Lp(a) ≥50 mg/dL		
	HR (95% CI)*	P value	I^2 (95% CI)	HR (95% CI)*	P value	I^2 (95% CI)	HR (95% CI)*	P value	I^2 (95% CI)
Baseline Lp(a)									
Basic adjustment: 7 trials – 29069 patients – 5751 events									
Age- and sex-adjusted	1·04 (0·91, 1·18)	0·59	43% (0, 76)	1·11 (1·00, 1·22)	0·047	0% (0, 71)	1·31 (1·08, 1·58)	0·005	73% (43, 88)
Progressive adjustment: 6 trials – 27764 patients – 5649 events									
Age- and sex-adjusted	1·03 (0·90, 1·18)	0·64	54% (0, 81)	1·10 (1·00, 1·22)	0·053	0% (0, 75)	1·30 (1·06, 1·59)	0·010	78% (52, 90)
Plus prior CVD	1·04 (0·90, 1·19)	0·61	53% (0, 81)	1·10 (1·00, 1·22)	0·049	0% (0, 75)	1·31 (1·07, 1·60)	0·009	78% (52, 90)
Plus diabetes	1·04 (0·91, 1·19)	0·60	52% (0, 81)	1·11 (1·01, 1·23)	0·036	0% (0, 75)	1·32 (1·08, 1·61)	0·007	78% (51, 90)
Plus smoking	1·03 (0·91, 1·18)	0·61	50% (0, 80)	1·11 (1·01, 1·22)	0·034	0% (0, 75)	1·31 (1·08, 1·59)	0·007	77% (48, 90)
Plus SBP	1·03 (0·90, 1·18)	0·64	53% (0, 81)	1·11 (1·01, 1·22)	0·031	0% (0, 75)	1·31 (1·07, 1·59)	0·008	77% (49, 90)
Plus LDL-C$_{corr}$	1·04 (0·90, 1·19)	0·61	55% (0, 82)	1·12 (1·02, 1·24)	0·019	0% (0, 75)	1·34 (1·09, 1·65)	0·005	78% (53, 90)
Plus HDL-C	1·04 (0·91, 1·20)	0·54	54% (0, 82)	1·13 (1·02, 1·25)	0·016	0% (0, 75)	1·35 (1·11, 1·66)	0·003	77% (49, 90)
On-statin Lp(a)									
Basic adjustment: 7 trials – 14536 patients – 2603 events									
Age- and sex-adjusted	0·94 (0·81, 1·10)	0·45	18% (0, 62)	1·06 (0·94, 1·21)	0·33	0% (0, 71)	1·43 (1·15, 1·76)	0·001	62% (13, 83)
Progressive adjustment: 6 trials – 13883 patients – 2561 events									
Age- and sex-adjusted	0·93 (0·79, 1·09)	0·37	18% (0, 63)	1·06 (0·93, 1·21)	0·35	0% (0, 75)	1·39 (1·12, 1·72)	0·002	64% (13, 85)
Plus prior CVD	0·93 (0·79, 1·09)	0·37	18% (0, 63)	1·06 (0·93, 1·21)	0·36	0% (0, 75)	1·39 (1·12, 1·72)	0·002	64% (13, 85)
Plus diabetes	0·94 (0·80, 1·10)	0·43	17% (0, 62)	1·07 (0·94, 1·22)	0·31	0% (0, 75)	1·39 (1·13, 1·71)	0·002	62% (7, 84)
Plus smoking	0·94 (0·81, 1·09)	0·42	8% (0, 77)	1·07 (0·94, 1·22)	0·30	0% (0, 75)	1·39 (1·13, 1·71)	0·002	62% (8, 84)
Plus SBP	0·94 (0·81, 1·09)	0·41	9% (0, 77)	1·07 (0·94, 1·22)	0·30	0% (0, 75)	1·39 (1·13, 1·71)	0·002	61% (6, 84)
Plus LDL-C$_{corr}$	0·94 (0·81, 1·10)	0·47	13% (0, 78)	1·08 (0·95, 1·23)	0·26	0% (0, 75)	1·41 (1·15, 1·73)	0·001	61% (3, 84)
Plus HDL-C	0·95 (0·82, 1·11)	0·53	13% (0, 78)	1·08 (0·95, 1·23)	0·24	0% (0, 75)	1·42 (1·16, 1·74)	0·001	58% (0, 83)

536
537 CI=confidence interval. CVD=cardiovascular disease. HDL-C=high-density lipoprotein cholesterol. HR=hazard ratio. LDL-C$_{corr}$=low-density-lipoprotein cholesterol corrected for Lp(a)-cholesterol. SBP=systolic blood pressure. *The group of patients with Lp(a) values <15 mg/dl served as reference group.

538

539 **Figure 1 – Shapes of associations of baseline and on-statin Lp(a) with incident**
540 **cardiovascular disease.**

541

542 Categories of Lp(a) were defined as <15 mg/dL, 15-<30 mg/dL, 30-<50 mg/dL, and ≥50 mg/dL. Numbers in squared
543 brackets are means of Lp(a) values within each category. The group with the lowest Lp(a) concentration served as reference.
544 The analysis of baseline Lp(a) involved 29069 patients (5751 events) in the age- and sex-adjusted model and 27764 patients
545 (5649 events) in the multivariable adjusted model. Corresponding numbers for the on-statin analysis were 14536 patients
546 (2603 events) and 13883 patients (2561 events), respectively. *The multivariable model was adjusted for age, sex, prior
547 cardiovascular disease, diabetes, smoking, systolic blood pressure, low-density-lipoprotein cholesterol corrected for Lp(a)-
548 cholesterol, and high-density lipoprotein cholesterol.

549

550 **Figure 2 – Comparative predictive value of on-statin vs. on-placebo Lp(a) for incident**
551 **cardiovascular disease.**

	No. of			HR (95% CI) comparing patients with Lp(a) ≥50 mg/dL vs. <50 mg/dL	P value for interaction
	Trials	Patients	Events		
Age- and sex-adjusted					
On-statin	7	14536	2603	1·48 (1·23, 1·78)	0·010
On-placebo	7	14533	3148	1·23 (1·04, 1·45)	
Multivariable adjusted*					
On-statin	6	13883	2561	1·47 (1·25, 1·73)	0·031
On-placebo	6	13881	3088	1·26 (1·06, 1·50)	

1   1.25   1.5 1.75   2

552

553 *The multivariable model was adjusted for age, sex, prior cardiovascular disease, diabetes, smoking, systolic blood pressure,
554 low-density-lipoprotein cholesterol corrected for Lp(a)-cholesterol, and high-density lipoprotein cholesterol.

Figure 3 – Associations of baseline and on-statin Lp(a) with incident cardiovascular disease by individual patient characteristics.

556

557   CI=confidence interval. HDL-C=high-density lipoprotein cholesterol. HR=hazard ratio. LDL-C$_{corr}$=low-density-lipoprotein cholesterol corrected for Lp(a)-cholesterol.

1   **Baseline and on-statin treatment lipoprotein(a) levels predict cardiovascular events:**
2   **An individual-patient-data meta-analysis of statin outcome trials**

3   **Brief title:** Lp(a) and CVD risk in statin outcome trials

4   Peter Willeit, Paul M. Ridker, Paul J. Nestel, John Simes, Andrew M. Tonkin, Terje R.
5   ~~Pederson~~Pedersen, Gregory G. Schwartz, Anders G. Olsson, Helen M. Colhoun, Florian
6   Kronenberg, Christiane Drechsler, Christoph Wanner, Samia Mora, Anastasia Lesogor,
7   Sotirios Tsimikas

8   Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria, and
9   Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
10   (~~Prof~~ P Willeit MD PhD); Brigham and Women's Hospital, Harvard Medical School, Boston,
11   MA, USA (Prof P M Ridker MD, Samia Mora, MD); Baker Heart & Diabetes Institute,
12   Melbourne, Australia (Prof P J Nestel MD); NHMRC Clinical Trials Centre, University of
13   Sydney, Australia (Prof J Simes MD ~~PhD~~); Department of Epidemiology and Preventive
14   Medicine, Monash University, Melbourne, Australia (Prof A M Tonkin MD); Oslo University
15   Hospital, Ullevål and Medical Faculty, University of Oslo, Oslo, Norway (Prof T R Pederson
16   MD); Division of Cardiology, VA Medical Center and University of Colorado School of
17   Medicine, Denver, CO, USA (Prof G G Schwartz MD PhD); Department of Medicine and
18   Care, Faculty of Health Sciences, University of Linköping, Linköping, Sweden (Prof A G
19   Olsson MD PhD); MRC Human Genetics Unit, Centre for Genomic and Experimental
20   Medicine, MRC Institute of Genetics & Molecular Medicine, Edinburgh, UK (Prof H
21   Colhoun MD); Division of Genetic Epidemiology, Department of Medical Genetics,
22   Molecular and Clinical Pharmacology, Medical University of Innsbruck, Innsbruck, Austria
23   (Prof F Kronenberg MD), Division of Nephrology, Department of Internal Medicine 1 and
24   Comprehensive Heart Failure Centre, University Hospital of Würzburg, Würzburg, Germany
25   (C Drechsler MD PhD, Prof C Wanner MD); Novartis Pharma AG, Basel, Switzerland (A
26   Lesogor MD); Vascular Medicine Program, Sulpizio Cardiovascular Center, Division of
27   Cardiology, Department of Medicine, University of California San Diego, La Jolla, CA, USA
28   (Prof S Tsimikas MD)

29   **Key words:** Lipoprotein(a), cardiovascular disease, statin, outcomes, meta-analysis

30   ~~3231~~ **3458** words, **3** tables, ~~2~~ **3** figures, **5** supplementary tables, **2** supplementary figures

31   **Correspondence to:** Associate ~~Professor~~ Peter Willeit MD PhD, Department of Neurology,
32   Medical University of Innsbruck, Innsbruck, Austria, phone: +43 512 504-83493; email:
33   peter.willeit@i‑med.ac.at; or Professor Sotirios Tsimikas MD, Vascular Medicine Program,

34   Sulpizio Cardiovascular Center, University of California San Diego, phone: +1 8585346109;

35   email: stsimikas@ucsd.edu.

Abstract (300 words)

Background: Elevated lipoprotein(a) [Lp(a)] is a genetic risk factor for cardiovascular disease (CVD) in general population studies, but its contribution to CVD risk in patients with established CVD or on statin therapy is uncertain.

Methods: Patient-level data from seven randomized placebo-controlled statin outcomes trials were collated and harmonized to calculate hazard ratios for CVD, defined as fatal or non-fatal coronary heart disease, stroke, or revascularisation procedures. Hazard ratios for CVD were estimated within each trial across pre-defined Lp(a) groups (15-<30, 30-<50, and ≥50 vs. <15 mg/dL), before pooling estimates using multivariate random-effects meta-analysis.

Findings: Analyses included data for 29069 patients with repeat Lp(a) measurements (mean age 62 years; 28% female; 5751 events during 95576 person-years at risk). Initiation of statin therapy reduced low-density-lipoprotein cholesterol (mean change [95% CI]: -~~38~~39% [-~~44~~43, -~~33~~35]) without a significant change in Lp(a). Associations of baseline and on-statin treatment Lp(a) with CVD risk were approximately linear with increased risk at Lp(a) values ≥30 mg/dL for baseline Lp(a) and ≥50 mg/dL for on-statin Lp(a). Age- and sex-adjusted hazard ratios across Lp(a) groups [referent: Lp(a) <15 mg/dL] were 1·04 (0·91, 1·18), 1·11 (1·00, 1·22), and 1·31 (1·08, 1·58) for baseline Lp(a), and 0·94 (0·81, 1·10), 1·06 (0·94, 1·21), and 1·43 (1·15, 1·76) for on-statin Lp(a). Hazard ratios were virtually identical after further adjustment for prior CVD, diabetes, smoking, systolic blood pressure, low-density-lipoprotein cholesterol, and high-density-lipoprotein cholesterol. The association of on-statin Lp(a) with CVD risk was stronger than for on-placebo Lp(a) (interaction P=0·010) and was more pronounced at younger ages (interaction P=0·008) without effect modification by any other patient-level or study-level characteristics.

Interpretation: In this individual-patient meta-analysis of statin-treated patients, elevated baseline and on-statin Lp(a) showed an independent, approximately linear relationship with CVD risk. This study provides a rationale for testing the Lp(a) lowering hypothesis in CVD outcomes trials.

Funding: Novartis Pharma AG provided support for the performance of the meta-analysis.

Introduction

Lipoprotein(a) [Lp(a)] is a lipoprotein composed of apolipoprotein(a) covalently bound to apolipoprotein B (apoB) of a low-density lipoprotein (LDL) like particle.[1,2] Lp(a) mediates atherogenicity via its LDL moiety that has a similar proportion of cholesterol content as traditional LDL particles. In addition, it induces pro-inflammatory responses[3,4] via accumulation of oxidised phospholipids[5] and potentially exerts pro-thrombotic effects via the plasminogen-like apolipoprotein(a) moiety.[6] In contrast to other major lipoproteins, there is no approved specific therapy to lower circulating plasma levels of Lp(a).

Epidemiologic[7] and genetic[8,9] evidence has accumulated over the last decade showing that elevated Lp(a), driven primarily by the *LPA* gene,[10] is associated with increased risk of coronary heart disease, stroke, peripheral arterial disease, and calcific aortic valve stenosis.[1,2,11] These data have established Lp(a) as a cardiovascular disease (CVD) risk factor, but the bulk of evidence is based on studies involving individuals without prior CVD and without intensive secondary prevention therapies. In contrast, the role of elevated Lp(a) in patients with prior CVD events or on statin therapy and other guideline-recommended therapies is less clear. Prior studies in this patient population yielded inconsistent results, with findings ranging from significant positive associations to null associations such as following acute coronary syndromes (reviewed in reference[2]). In addition, several studies, including JUPITER[12] and AIM-HIGH[13], have shown that elevated Lp(a) remain predictive for CVD risk at LDL-cholesterol (LDL-C) levels <70 mg/dL,[1] but other studies suggest a positive association only when LDL-C is elevated.[14] Furthermore, a major limitation of all post hoc studies reporting Lp(a) levels and outcomes~~,~~ is that they involved only a small number of patients with Lp(a) values above 50 mg/dL and therefore were ~~none recruited patients with elevated Lp(a) *a priori*, and therefore the entry Lp(a) levels are usually in the normal range in 70%-80% of study participants. Therefore, all studies thus far have relied on subgroup analyses and are~~ uniformly underpowered to test the hypothesis that elevated Lp(a) levels ~~in the setting of statin therapy and prior history of CVD~~ are associated with increased CVD risk in the setting of statin therapy or prior history of CVD.

To test this hypothesis with adequate statistical power, we established the Lipoprotein(a) Studies Collaboration, a consortium of patient-level data from placebo-controlled trials of statins with patient-level data on CVD outcomes and Lp(a) measurements at baseline and follow-up (i.e. under statin treatment). We now report the results of this analysis in documenting the associations of baseline and on-treatment Lp(a) with cardiovascular risk.

Methods

Trials included in the meta-analysis

To be eligible in the meta-analysis, randomized placebo-controlled statin trials were required to have assayed Lp(a) concentration at baseline and follow-up, have recorded incidence of CVD outcomes using well-defined criteria, and be willing to share patient data at the individual-level. We included data from AFCAPS, CARDS, 4D, JUPITER, LIPID, MIRACL, and 4S. Their study design, target population, and entry criteria are summarised in **Table 1**; more detailed descriptions of trial designs[15–21] and Lp(a) methodology and data[12,22–26] were previously reported by each trial. Trials not included in the meta-analysis were either not allowed or willing to provide individual-level patient data. Due to contractual agreements

109   on sharing individual patient data, other eligible trials could not be included in the meta-
110   analysis. All contributing trials have obtained ethics approval and patients' informed consent.

111 **Statistical analyses**
112 Analyses were conducted according to a pre-specified analysis plan, developed prior to any
113 combined analyses. Lp(a) values were log_e-transformed. Of 45044 patients enrolled in the
114 seven trials, 15975 (35·5%) patients were excluded because of missing Lp(a) measurements
115 at both baseline and follow-up, leaving 29069 patients for analysis (for CONSORT diagram,
116 please refer to **Supplementary Figure 1**). ~~Clinical~~There were minimal differences in
117 baseline characteristics of patients with or without available Lp(a) measurements ~~excluded~~
118 ~~were similar to those of patients included in the analysis~~ (**Supplementary Table 1**). In all
119 trials except 4S, on-statin Lp(a) during follow-up was measured at one time-point. In the 4S
120 trial, on-statin Lp(a) was estimated as the geometric mean of Lp(a) values assessed at up to
121 four distinct time points. Lp(a) values provided in nmol/L were divided by 2·4 (JUPITER), as
122 previously described[27], and those provided in IU/L by 19·07 (4S) to convert them to the
123 common unit of mg/dL. When information on Lp(a) was missing either at baseline (0·5%) or
124 at follow-up (5·5%), their Lp(a) value was mean-imputed from study-specific mixed-effects
125 models which predicted Lp(a) values using fixed effects for assigned treatment, time-in-
126 study, and the interaction of the two variables, plus a random intercept allowed to vary at the
127 patient level~~included fixed effects of Lp(a) values available for that patient at other time~~
128 ~~points, the time between repeat measurements, and trial arm, plus random effects at the~~
129 ~~patient level~~.

130 Because conventional "LDL-C" assays capture cholesterol both in LDL and Lp(a) particles,
131 LDL-C values were corrected for the latter. Lp(a) mass in mg/dL is composed of ~30-45%
132 cholesterol.[28] We used a conservative measurement of the content of Lp(a)-C by multiplying
133 Lp(a) mass (in mg/dL) by 0·30 to derive Lp(a)-cholesterol, and then subtracting this value
134 from the measured LDL-C to obtain corrected LDL-C (LDL-C$_{corr}$).[28]

135 The combined CVD endpoint was defined as the occurrence of fatal or non-fatal coronary
136 heart disease, stroke, or any coronary or carotid revascularisation procedures. In analysing
137 on-treatment Lp(a), all CVD events that occurred after randomisation were considered
138 because any change in Lp(a) under statin therapy is anticipated to occur within a short time
139 period (sensitivity analyses omitted the initial period of follow-up).[12]

140 Associations of Lp(a) with CVD risk were estimated using a two-step approach, with
141 estimates calculated within each study separately before pooling them across studies using
142 multivariate random-effects meta-analysis.[29] ~~The analysis of baseline Lp(a) involved all~~
143 ~~patients, whereas the analysis of on-treatment Lp(a) was restricted to patients assigned to the~~
144 ~~intervention arm.~~ Hazard ratios were calculated using Cox proportional hazard regression
145 models which used time-on-study as a timescale, were stratified by trial arm, and compared
146 the pre-specified Lp(a) groups <15 mg/dL, 15-<30 mg/dL, 30-<50 mg/dL, and ≥50 mg/dL.
147 The assumption~~s~~ for the proportionality of hazards was tested using Schoenfeld residuals and
148 ~~were~~ was met. The analysis had four inter-related principal aims. First, to evaluate shapes of
149 associations, pooled hazard ratios were calculated over Lp(a) groups and plotted against the
150 pooled geometric mean of Lp(a) concentration within each category.[29] Second, to determine
151 the extent of confounding, hazard ratios were progressively adjusted for age, sex, prior CVD,
152 diabetes, smoking, systolic blood pressure, LDL-C$_{corr}$, and high-density-lipoprotein-
153 cholesterol ("multivariable adjusted model"). Further adjustment for body-mass index and
154 estimated glomerular filtration rate was employed in the subset of patients, in which these
155 data were available. Third, to investigate whether the predictive value of follow-up Lp(a)

156 differed between patients randomized to statin vs. placebo, interaction models by trial arm
157 were fitted. Fourth, to investigate effect modification by individual-patient and study-level
158 characteristics, formal tests of interaction and meta-regression analyses with these variables
159 were performed. There was little variability within each trial of the proportion of patients
160 with prior CVD and with a history of diabetes at baseline (e.g. secondary vs. primary CVD
161 prevention trials, diabetes as inclusion or exclusion criterion) and hence effect modification
162 by these characteristics was investigated at the study-level instead of at the patient-level.
163 Between-trial heterogeneity was assessed with the I^2 statistic.[30] Analyses were performed
164 using Stata (version 14·1 MP) and involved two-sided statistical tests and 95% confidence
165 intervals. Principal analyses used a significance level of P<0·05 and subgroup analyses a
166 Bonferroni-corrected significance level of P<0·007 (for seven subgroups).

Role of funding source

168 The funders of the study had no role in study design, data collection, data analysis, data
169 interpretation, or writing of the report. PW and ST had full access to all the data in the study
170 and had final responsibility for the decision to submit for publication.

171 # Results

172 **Summary of available data**

173 Data on 29069 patients from seven contributing trials were analysed (**Table 2**). At trial entry,
174 mean age was 62 years (SD 8), 8064~~28%~~ were female (28%), 15252~~52%~~ had prior CVD
175 (52%), 5177~~18%~~ had diabetes (18%), 4847~~17%~~ were current smokers (17%), mean systolic
176 blood pressure was 137 mmHg (SD 18), and mean LDL-C$_{corr}$ was 3·30 mmol/L (SD 0·67).
177 Median concentration of Lp(a) at baseline was in low normal range of 11 mg/dL
178 (interquartile range: 5-29). In cross-sectional analyses, baseline Lp(a) concentration was
179 higher in females (+12% [3, 21]), lower in patients with diabetes (-17% [-24, -9]) and
180 unrelated to smoking (+2% [-3, 8]). Furthermore, LDL-C$_{corr}$, log$_e$ triglycerides, body-mass
181 index, and systolic blood pressure were associated with a lower and HDL-C with a higher
182 Lp(a) concentration (age-and sex-adjusted differences in Lp(a) per SD: -16% [-23, -8], -12%
183 [-15, -9], -7% [-10, -5], -2% [-5, -0], and +7% [3, 11]). Baseline Lp(a) was not associated
184 with age (-1% [-2, 1] per SD).

185 A total of 14,536 patients were randomized to receive statin therapy (**Table 2**). Initiation of
186 statin therapy reduced LDL-C$_{corr}$ by -38~~39~~% (95% confidence interval: -44~~43~~, -33~~35~~). The
187 effect of statin on Lp(a) concentration was heterogeneous across trials; the pooled percentage
188 change was -0·4% (-7, 7), with three trials showing a mean increase (range +2 to +15%) and
189 four trials showing a mean decrease (range -1 to -13%) in Lp(a). The median concentration of
190 Lp(a) on statin therapy was 11 mg/dL (interquartile range: 5-32). The age- and sex-adjusted
191 correlation between baseline and follow-up log$_e$ Lp(a) was comparable in the statin arm and
192 the placebo arm (r=0.948 vs. 0.952).

193 **Associations of baseline and on-statin Lp(a) with cardiovascular disease risk**

194 During 95576 person-years at risk (median follow-up 3·0 years [interquartile range: 1·5-
195 5·3]), a total of 5751 CVD events were recorded, of which 2603 occurred in the statin arm
196 (**Table 2**). When patients were grouped by Lp(a) concentration into the categories <15
197 mg/dL, 15-<30 mg/dL, 30-<50 mg/dL, and ≥50 mg/dL, incidence rates for CVD (95% CI)
198 per 1000 person-years were as follows: 55·3 (53·4-57·3), 56·3 (52·6-60·2), 66·7 (62·0-71·8),

199 and 80·0 (75·3-84·9) for baseline Lp(a), and 49·0 (46·5-51·6), 46·4 (41·6-51·7), 56·2 (50·3-
200 62·8), and 77·2 (71·1-83·8) for on-statin Lp(a).

201 In analyses adjusted for age and sex only, associations of baseline and on-statin Lp(a) values
202 with the risk of CVD were of positive approximately linear shape, with a possible threshold
203 effect in the group with Lp(a) values of 50 mg/dL or more (**Figure 1**). For baseline Lp(a), the
204 hazard ratios compared to patients with Lp(a) values of <15 mg/dL were 1·04 (0·91, 1·18)
205 with Lp(a) values 15-<30 mg/dL, 1·11 (1·00, 1·22) with Lp(a) values 30-<50 mg/dL, and
206 1·31 (1·08, 1·58) with Lp(a) values ≥50 mg/dL (**Table 3**). For on-statin Lp(a), corresponding
207 hazard ratios were 0·94 (0·81, 1·10), 1·06 (0·94, 1·21), and 1·43 (1·15, 1·76).

208 Associations ~~were~~ remained robust to additional ~~multivariable~~ adjustment for ~~age, sex,~~ prior
209 CVD, diabetes, smoking, systolic blood pressure, LDL-C$_{corr}$, and HDL-C concentration
210 (**Figure 1** and **Table 3**). Corresponding hazard ratios were 1·04 (0·91, 1·20), 1·13 (1·02,
211 1·25), and 1·35 (1·11, 1·66) for baseline Lp(a) and 0·95 (0·82, 1·11), 1·08 (0·95, 1·23), and
212 1·42 (1·16, 1·74) for on-statin Lp(a). In a sensitivity analysis of patients with information on
213 triglycerides, body-mass index, or estimated glomerular filtration rate, further adjustment for
214 these parameters did not materially change the magnitude of association between Lp(a)
215 measurements and CVD risk (**Supplementary Table 2**). Effect sizes comparable with those
216 in the principal analysis were observed when further categorising the highest Lp(a) group into
217 patients with levels 50-<75 mg/dL and ≥75 mg/dL (**Supplementary Table 3**) and in the on-
218 statin analysis when omitting events that occurred in the initial period between randomization
219 and on-statin measurement of Lp(a) (**Supplementary Table 4**). Trial-specific findings are
220 provided in **Supplementary Table 5**.

221 **Comparative predictive value of on-statin vs. on-placebo Lp(a)**

222 Lp(a) concentration measured during follow-up was more strongly associated with CVD risk
223 in the on-statin arm than in the on-placebo arm (**Figure 2**). In comparison of patients with
224 Lp(a) ≥50 mg/dL with those having Lp(a) <50 mg/dL, the age- and sex-adjusted hazard ratios
225 for CVD were 1·48 (1·23 to 1·78) for on-statin Lp(a) and 1·23 (1·04 to 1·45) for on-placebo
226 Lp(a) (interaction P=0·010). The corresponding multivariable adjusted hazard ratios were
227 1·47 (1·25 to 1·73) and 1·26 (1·06 to 1·50) (interaction P=0·031). The median time from
228 randomization to Lp(a) repeat was 1.0 years in both trial arms.

229 **Associations according to patient-level and study-level characteristics**

230 There was some heterogeneity between trials in hazard ratios for CVD, most pronounced in
231 the group with a Lp(a) concentrations ≥50 mg/dL. For example, in this group, I^2 values of
232 age- and sex-adjusted hazard ratios were 73% (43, 88) for baseline Lp(a) and 62% (13, 83)
233 for on-statin Lp(a) (**Table 3**). Apart from stronger associations of on-statin Lp(a) with CVD
234 risk at younger age (<60 years vs. 60-<70 years vs. ≥70 years; interaction P=0·008), hazard
235 ratios did not vary significantly across clinically relevant subgroups, such as by sex, smoking,
236 systolic blood pressure, lipid parameters, or body-mass index (**Figure 3**). Furthermore, the
237 magnitude of association was independent of a study's proportion of patients with prior CVD
238 or diabetes, the length of follow-up for clinical events, and the time between study baseline
239 and follow-up on-statin Lp(a) measurement (**Supplementary Figure 2**). Contributing trials
240 employed differing statin interventions, precluding a subgroup analysis by statin type or
241 statin dosage.

Discussion

This well-powered meta-analysis of Lp(a) and CVD events reveals that patients with elevated Lp(a) on statin therapy, primarily with levels of >50 mg/dL, are at a significantly higher risk of CVD. The association with CVD risk was independent of conventional CVD risk factors, as also reflected in the very weak or null cross-sectional correlations of Lp(a) with these risk factors. Importantly, hazard ratios for high Lp(a) at baseline and under statin therapy were of similar magnitude, reflecting that statin therapy may not appreciably affect Lp(a)-mediated risk in patients with elevated Lp(a). Overall, these data suggest that patients with elevated Lp(a), representing ~25% of subjects with prior CVD or statin indication,[1] are at substantial residual risk even under statin therapy. In this patient population, therapies which specifically lower Lp(a) might mitigate Lp(a)-mediated risk. An appropriately designed CVD outcomes trial with robust Lp(a)-lowering is therefore justified to test the hypothesis that lowering Lp(a) reduces CVD events, independent of statin treatment.

At baseline, Lp(a) levels were weakly associated with demographic and laboratory variables. The most significant but nevertheless weak correlations were inverse with diabetes mellitus and triglycerides. The observation of an inverse association of Lp(a) with incident diabetes has been made previously,[31] and is most pronounced at very low levels of Lp(a) (≤5 mg/dL), which are present in the 10th percentile of the global population.[1,2] It has not been determined if the findings are causal or if there is confounding by reverse causality.[32] Although the underlying mechanisms are not well understood, fasting and post-prandial insulin levels are inversely associated with Lp(a).[33] Lp(a) was weakly correlated with LDL-C, but this relationship became inversely associated after subtracting the estimated cholesterol content in Lp(a) from the laboratory measurement called "LDL-C".[28]

Prior studies evaluating the role of Lp(a) in predicting CVD in patients without CVD, using Lp(a) assays in the modern era that lack limitations of prior assays, have been almost uniformly positive.[7] However, studies in patients with prior CVD or on statin therapy have been mixed, or have suggested the effect is present primarily in patients with elevated LDL-C (reviewed in Tsimikas et al.[2]). A major limitation of all substudies reporting Lp(a) and outcomes has been power. All studies have enrolled patients with Lp(a) levels in the mid to low normal range (10-15 mg/dL, normal <30 mg/dL), as confirmed in the current meta-analysis, thus statistical power to evaluate risk in patients with highly elevated Lp(a) (i.e. >50 mg/dL) was limited. The current study is highly powered with 5751 total events and 2603 events in the statin arms, making it equivalent to, or larger than, most individual randomised controlled cardiovascular outcome trials in the modern era. In contrast to a previous analysis of individual-patient data by O'Donoghue et al,[34] our study afforded higher statistical power because it involved >10 times more CVD events, and hence was able to characterise associations with high Lp(a) concentrations more precisely. Moreover, the present analysis used clinically-relevant Lp(a) categories informed by guideline recommendations, as opposed to trial-specific quintiles.

The current meta-analysis is also highly representative of clinical care in patients treated with statins. First, these studies represent patients ~~that~~ who were treated with moderate-high doses of the five major statins used clinically. Second, they reflect the variety of patients treated clinically, including primary prevention, high-risk primary prevention with elevated C-reactive protein or diabetes, secondary prevention, stable coronary artery disease, ~~diabetes,~~ acute coronary syndromes, patients on dialysis and highly elevated LDL-C in the familial hypercholesterolemia range. Therefore, they broadly reflect ~~the~~ patients with high residual

288 risk despite statin treatment, potentially due to other, unmodified risk factors such as elevated
289 Lp(a)at risk for Lp(a)-mediated CVD.

290 The risk thresholds chosen reflect clinical risk as suggested by epidemiologic and genetic
291 studies. The reference cutoff of <15 mg/dL, reflects roughly the median global level of
292 Lp(a).[35,36] Lp(a) <30 mg/dL represents the usual cutoff in US laboratories that is considered
293 as normal level, and is based on data showing that risk of myocardial infarction starts to
294 accrue at levels above 25-30 mg/dL.[7,37] The range of 30-50 mg/dL was chosen as this is the
295 grey zone between what is considered pathophysiologically relevant and >50 mg/dL is based
296 on what the European Atherosclerosis Society as considered elevated levels at highest risk
297 based on the European population prevalence of 20%.

298 In this study, elevation of CVD risk became evident at baseline Lp(a) 30 to <50 mg/dL and
299 was further pronounced when Lp(a) levels exceeded 50 mg/dL, including patients treated
300 with statins. The hazard ratios for Lp(a) ≥50 mg/dL are consistent with recent PCSK9
301 inhibitor studies in patients with background statin therapy.[38] Additional analyses at even
302 higher Lp(a), i.e. ≥75 mg/dL were limited by low power due to small numbers of patients
303 with Lp(a) levels in this range, but support a graded relationship of Lp(a) with cardiovascular
304 risk. Outcome trials of Lp(a) lowering are likely to include patients with mean baseline Lp(a)
305 substantially >50 mg/dL, therefore, extrapolation to event reduction with Lp(a) lowering
306 from these data may be an underestimate.

307 A key observation of this study is that on-statin Lp(a) was more strongly associated with
308 CVD risk than on-placebo Lp(a). -A small angiographic study initially suggested that the risk
309 of Lp(a) is attenuated when LDL-C is well controlled.[39] In contrast, the current study,
310 utilising a far larger body of data, supports the opposite conclusion that risk is independently
311 associated with both LDL-C and Lp(a). When LDL-attributable risk is reduced with statin
312 treatment, Lp(a)-associated risk becomes an even stronger predictor of residual risk. This
313 observation is particularly evident at Lp(a) levels exceeding 50 mg/dL. In support of our
314 observation in this study, the trials FOURIER (European Atherosclerosis Society, May 2018)
315 and ODYSSEY OUTCOMES (International Atherosclerosis Society, June 2018) have
316 recently presented preliminary findings of their data, both showing that elevated baseline
317 Lp(a) remains a risk factor even with on-treatment LDL-C <50 mg/dL in patients treated with
318 statins and PCSK9 inhibitors. The findings raise the importance of determining whether there
319 is a cardiovascular benefit of treatment to reduce Lp(a) when initial levels exceed this
320 threshold, irrespective of concurrent treatment with statin. A second important observation is
321 that all major subgroups of patients seemed to be at risk of elevated Lp(a), including those
322 >70 years old, females, smokers, those with low and high LDL-C$_{corr}$, low HDL-C and all
323 categories of body-mass index. The current study suggests that the relationship of Lp(a) to
324 risk is curvilinear if plotted on a geometric mean scale, but linear if plotted on continuous
325 scale, suggesting that potent reduction in Lp(a) may be clinically beneficial across all
326 elevated Lp(a) levels.

327 It is important to emphasize that the Lp(a) hypothesis remains to be tested. To do so requires
328 a randomized trial that compares cardiovascular outcomes in patients treated with an agent
329 that specifically lowers Lp(a) versus placebo. Such a trial may be possible with antisense
330 oligonucleotide targeting *LPA* messenger RNA, thereby reducing plasma Lp(a) levels. Phase
331 I and II trials with this agent have shown the potential to lower Lp(a) levels by over 90%
332 without major effects on other classes of lipoproteins.[27,40]

One limitation of this study is that individual-patient data could not be obtained from several other statin trials that reported Lp(a) levels and outcomes. It is possible that inclusion of other data would have modified the observed effect sizes. Secondly, the relationship of Lp(a) to residual cardiovascular risk under treatment with non-statin lipid-modifying agents (e.g., ezetimibe, PCSK9 inhibitors) remains undetermined. Third, the Lp(a) assays were heterogeneous and most were in Lp(a) mass rather than in Lp(a) molar concentration and the timepoints at which they were measured in each trial were not uniform. Therefore, the assays not reported in mg/dL had to be mathematically converted to mg/dL, which may have introduced imprecision into introduce bias into the Lp(a) measurement precision. A recent NHLBI Working Group on Lp(a) recommended global standardization of Lp(a) assays to address this limitation.[2] Fourth, we cannot rule out that index event bias may have attenuated effect sizes in secondary prevention trials, although the scope of this bias was reduced by employment of multivariable adjustment. Fifth, our analysis identified moderate to high between-study heterogeneity, which could not be explained by baseline disease status (i.e. prior CVD or prior diabetes) nor by differing lengths of follow-up periods. Finally, the data for the change in Lp(a) post statin therapy was heterogeneous across studies, with both increases and decreases, but no net change. Due to different assays used in each of the trials, and the need for conversion of all data to mg/dL, and the hihgerhigher precision required to show intra-individual changes, these data should be considered hypothesis generating. A more robust test of this particular hypothesis should ideally be performed using the same assay.

In conclusion, this meta-analysis demonstrates an approximately linear relationship of cardiovascular risk to levels of Lp(a), evident at Lp(a) levels 30-50 mg/dL, pronounced at levels ≥50 mg/dL, and persisting despite statin treatment. These data provide a rationale for evaluating drugs that can specifically lower Lp(a) and might have the potential to reduce residual cardiovascular risk independent of statin treatment.

Contributors

PW and ST wrote the analysis plan, collected and harmonized the data, and wrote the first draft of the manuscript. PW and ST had access to all the raw data and PW performed the statistical analysis. PMR, PJN, JS, AMT, TRP, GGS, AGO, HMC, FK, CD, CW, and SM CW have collected patient data in statin trials and provided cleaned data to the coordinating centre. All authors provided contributed to writing the final report and approved the version to be submitted to the journal.

PJN, TRP, GGS, AGO, CW, PMR, and HC have contributed to data acquisition as principal investigators of statin trials. PW and ST wrote the analysis plan, collected and harmonized the data, and wrote the first draft of the manuscript. PW and ST had access to all the raw data and PW performed the statistical analysis. All authors contributed to writing the final report and approved the version to be submitted to the journal.

Declaration of interests

PW reports consultancy fees from Novartis Pharmaceuticals during the conduct of the study, and travel expenses from Bayer, Daiichi Sankyo, and Sanofi-Aventis outside the submitted work. PMR reports grants from AstraZeneca during the conduct of the study, grants from, Novartis, Kowa, Pfizer, and NHLBI outside of the submitted work, and personal fees from

Acknowledgements

References

1 Tsimikas S. A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies. *J Am Coll Cardiol* 2017; **69:** 692–711.

2 Tsimikas S, Fazio S, Ferdinand KC, et al. NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis. *J Am Coll Cardiol* 2018; **71:** 177–92.

3 van der Valk FM, Bekkering S, Kroon J, et al. Oxidized Phospholipids on Lipoprotein(a) Elicit Arterial Wall Inflammation and an Inflammatory Monocyte Response in Humans. *Circulation* 2016; **134:** 611–24.

4 Wiesner P, Tafelmeier M, Chittka D, et al. MCP-1 binds to oxidized LDL and is carried by lipoprotein(a) in human plasma. *J Lipid Res* 2013; **54:** 1877–83.

5 Leibundgut G, Scipione C, Yin H, et al. Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a). *J. Lipid Res.* 2013; **54:** 2815–30.

6 Boffa MB, Koschinsky ML. Lipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease? *J Lipid Res* 2016; **57:** 745–57.

421   7   Emerging Risk Factors Collaboration. Lipoprotein(a) concentration and the risk of
422   coronary heart disease, stroke, and nonvascular mortality. *JAMA* 2009; **302:** 412–23.
423   8   Clarke R, Peden JF, Hopewell JC, et al. Genetic variants associated with Lp(a) lipoprotein
424   level and coronary disease. *N Engl J Med* 2009; **361:** 2518–28.
425   9   Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated
426   lipoprotein(a) and increased risk of myocardial infarction. *JAMA* 2009; **301:** 2331–39.
427   10 Schmidt K, Noureen A, Kronenberg F, Utermann G. Structure, function, and genetics of
428   lipoprotein (a). *J Lipid Res* 2016; **57:** 1339–59.
429   11 Thanassoulis G, Campbell CY, Owens DS, et al. Genetic associations with valvular
430   calcification and aortic stenosis. *N Engl J Med* 2013; **368:** 503–12.
431   12 Khera AV, Everett BM, Caulfield MP, et al. Lipoprotein(a) concentrations, rosuvastatin
432   therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for
433   the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin).
434   *Circulation* 2014; **129:** 635–42.
435   13 Albers JJ, Slee A, O'Brien KD, et al. Relationship of apolipoproteins A-1 and B, and
436   lipoprotein(a) to cardiovascular outcomes. The AIM-HIGH trial (Atherothrombosis
437   Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on
438   Global Health Outcomes). *J Am Coll Cardiol* 2013; **62:** 1575–79.
439   14 O'Donoghue ML, Morrow DA, Tsimikas S, et al. Lipoprotein(a) for risk assessment in
440   patients with established coronary artery disease. *J Am Coll Cardiol* 2014; **63:** 520–27.
441   15 Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with
442   lovastatin in men and women with average cholesterol levels: results of
443   AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. *JAMA*
444   1998; **279:** 1615–22.
445   16 Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular
446   disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes
447   Study (CARDS): multicentre randomised placebo-controlled trial. *Lancet* 2004; **364:**
448   685–96.
449   17 Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in
450   men and women with elevated C-reactive protein. *N Engl J Med* 2008; **359:** 2195–207.
451   18 Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group.
452   Prevention of cardiovascular events and death with pravastatin in patients with coronary
453   heart disease and a broad range of initial cholesterol levels. *N Engl J Med* 1998; **339:**
454   1349–57.
455   19 Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent
456   ischemic events in acute coronary syndromes: the MIRACL study: a randomized
457   controlled trial. *JAMA* 2001; **285:** 1711–18.
458   20 Scandinavian Simvastatin Survival Study. Randomised trial of cholesterol lowering in
459   4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study
460   (4S). *Lancet* 1994; **344:** 1383–89.
461   21 Krane V, Schmidt K-R, Gutjahr-Lengsfeld LJ, et al. Long-term effects following 4 years
462   of randomized treatment with atorvastatin in patients with type 2 diabetes mellitus on
463   hemodialysis. *Kidney Int* 2016; **89:** 1380–87.
464   22 Deshmukh HA, Colhoun HM, Johnson T, et al. Genome-wide association study of genetic
465   determinants of LDL-c response to atorvastatin therapy: importance of Lp(a). *J Lipid Res*
466   2012; **53:** 1000–11.
467   23 Kollerits B, Drechsler C, Krane V, et al. Lipoprotein(a) concentrations, apolipoprotein(a)
468   isoforms and clinical endpoints in haemodialysis patients with type 2 diabetes mellitus:
469   results from the 4D Study. *Nephrol Dial Transplant* 2016; **31:** 1901–08.

470 24 Nestel PJ, Barnes EH, Tonkin AM, et al. Plasma lipoprotein(a) concentration predicts
471   future coronary and cardiovascular events in patients with stable coronary heart disease.
472   *Arterioscler Thromb Vasc Biol* 2013; **33:** 2902–08.

473 25 Tsimikas S, Witztum JL, Miller ER, et al. High-dose atorvastatin reduces total plasma
474   levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100
475   in patients with acute coronary syndromes in the MIRACL trial. *Circulation* 2004; **110:**
476   1406–12.

477 26 Berg K, Dahlén G, Christophersen B, Cook T, Kjekshus J, Pedersen T. Lp(a) lipoprotein
478   level predicts survival and major coronary events in the Scandinavian Simvastatin
479   Survival Study. *Clin Genet* 1997; **52:** 254–61.

480 27 Tsimikas S, Viney NJ, Hughes SG, et al. Antisense therapy targeting apolipoprotein(a): a
481   randomised, double-blind, placebo-controlled phase 1 study. *Lancet* 2015; **386:** 1472–83.

482 28 Yeang C, Witztum JL, Tsimikas S. 'LDL-C' = LDL-C + Lp(a)-C: implications of
483   achieved ultra-low LDL-C levels in the proprotein convertase subtilisin/kexin type 9 era
484   of potent LDL-C lowering. *Curr Opin Lipidol* 2015; **26:** 169–78.

485 29 Thompson S, Kaptoge S, White I, et al. Statistical methods for the time-to-event analysis
486   of individual participant data from multiple epidemiological studies. *Int. J. Epidemiol.*
487   2010; **39:** 1345–59.

488 30 Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med*
489   2002; **21:** 1539–58.

490 31 Paige E, Masconi KL, Tsimikas S, et al. Lipoprotein(a) and incident type-2 diabetes:
491   results from the prospective Bruneck study and a meta-analysis of published literature.
492   *Cardiovasc Diabetol* 2017; **16:** 38.

493 32 Tsimikas S. In Search of a Physiological Function of Lp(a): Causality of Elevated Lp(a)
494   levels and Reduced Incidence of Type-2 Diabetes Mellitus. *J Lipid Res* 2018.

495 33 Rainwater DL, Haffner SM. Insulin and 2-hour glucose levels are inversely related to
496   Lp(a) concentrations controlled for LPA genotype. *Arterioscler Thromb Vasc Biol* 1998;
497   **18:** 1335–41.

498 34 O'Donoghue ML, Morrow DA, Tsimikas S, et al. Lipoprotein(a) for risk assessment in
499   patients with established coronary artery disease. *Journal of the American College of*
500   *Cardiology* 2014; **63:** 520–27.

501 35 Varvel S, McConnell JP, Tsimikas S. Prevalence of Elevated Lp(a) Mass Levels and
502   Patient Thresholds in 532 359 Patients in the United States. *Arterioscler Thromb Vasc*
503   *Biol* 2016; **36:** 2239–45.

504 36 Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a cardiovascular risk
505   factor: current status. *Eur Heart J* 2010; **31:** 2844–53.

506 37 Kostner GM, Avogaro P, Cazzolato G, Marth E, Bittolo-Bon G, Qunici GB. Lipoprotein
507   Lp(a) and the risk for myocardial infarction. *Atherosclerosis* 1981; **38:** 51–61.

508 38 Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and Clinical Outcomes in
509   Patients with Cardiovascular Disease. *N Engl J Med* 2017; **376:** 1713–22.

510 39 Maher VM, Brown BG, Marcovina SM, Hillger LA, Zhao XQ, Albers JJ. Effects of
511   lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a). *JAMA*
512   1995; **274:** 1771–74.

513 40 Viney NJ, van Capelleveen JC, Geary RS, et al. Antisense oligonucleotides targeting
514   apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind,
515   placebo-controlled, dose-ranging trials. *Lancet* 2016; **388:** 2239–53.

516

Research in context

Evidence before this study: Lp(a) has been associated with increased risk of incident cardiovascular disease in primary care populations, but its role in predicting cardiovascular events in ~~the risk of~~ high-risk patients ~~in the setting of statin therapy is not known~~ treated with statins is unclear. We searched PubMed for relevant clinical trials published up to July 9, 2018, using the search terms "Lipoprotein(a)" or "Lp(a)", plus "statin" and "cardiovascular diseases"[MeSH]. Our review identified seven statin trials (4D, 4S, FLARE, JUPITER, LIPID, MIRACL, and TNT), which reported on the association of Lp(a) with cardiovascular risk. The interpretation of the available evidence is complicated by inconsistent findings across trials (positive vs. null associations), limited statistical power of single trials, limited availability of follow-up Lp(a) measurements, and differing definitions of Lp(a) categories across trials.

Added value of this study: We obtained patient-level data in seven placebo-controlled statin trials encompassing 29069 patients and analysed the relationship of baseline and on-treatment Lp(a) ~~in the setting of statin therapy~~ to risk of major adverse cardiovascular events. Elevated Lp(a) of 50 mg/dL or higher, at baseline or on-treatment, was associated with an increased hazard ratio of cardiovascular ~~disease~~ events independent of other cardiovascular risk factors and evident on treatment with either statin or placebo.

Implications of all the available evidence: These data suggest that residual risk ~~in~~ is present in patients with elevated Lp(a) that is not addressed by statins and supports the rationale for outcomes trials to test specific therapies to lower Lp(a).

Tables

Table 1 – Design features of contributing trials.

Cohort	Years of baseline	Target population	Lipid entry criteria, mmol/L	Comparator to placebo	CVD outcome definition				
					MI	Stable angina	Stroke	Revascularisation	Other
AFCAPS[15]	1990-1993	Primary prevention	TC 4·65-6·82, LDL-C 3·36-4·91, TG ≤4·52, HDL-C ≤1·16♂ and ≤1·22♀	Lovastatin 20mg	●	●	●	●	●*
CARDS[22]	1997-2001	Type 2 diabetes	LDL-C ≤4·14, TG ≤6·78	Atorvastatin 10mg	●	○	●	●	○
4D[23]	1998-2002	Type 2 diabetes + hemodialysis	LDL-C 2·07-4·92, TG ≤11·3	Atorvastatin 20mg	●	○	●	●	○
JUPITER[12]	2003-2006	Primary prevention with C-reactive protein >2mg/dL	LDL-C <3·4, TG <5·65	Rosuvastatin 20mg	●	○	●	●	●†
LIPID[24]	1990-1992	Prior myocardial infarction or unstable angina	TC 4·0-7·0, TG <5·0	Pravastatin 40mg	●	○	●	●	○
MIRACL[25]	1997-1999	Acute coronary syndrome	TC <7·0	Atorvastatin 80mg	●	○	●	●	○
4S[26]	1989-1990	Prior myocardial infarction or angina	TC 5·5-8·0, TG ≤2·5	Simvastatin 20mg	●	○	○	●	○

Table 2 – Patient characteristics.

	AFCAPS	CARDS	4D	JUPITER	LIPID	MIRACL	4S	Total
Baseline								
No. of patients	1005	2470	1249	9612	7863	2431	4439	29069
Lp(a), mg/dL, median (IQR)	7 (3-17)	9 (5-22)	12 (5-42)	11 (5-23)	14 (7-44)	10 (5-29)	10 (4-28)	11 (5-29)
<15 mg/dL	733 (73)	1658 (67)	709 (57)	5896 (61)	4118 (52)	1481 (61)	2654 (60)	17249 (59)
15-<30 mg/dL	134 (13)	310 (13)	129 (10)	1867 (19)	1147 (15)	362 (15)	781 (18)	4730 (16)
30-<50 mg/dL	84 (8)	212 (9)	140 (11)	851 (9)	877 (11)	223 (9)	714 (16)	3101 (11)
≥50 mg/dL	54 (5)	290 (12)	271 (22)	998 (10)	1721 (22)	365 (15)	290 (7)	3989 (14)
Age, yrs	59 (7)	62 (8)	66 (8)	66 (8)	61 (8)	65 (11)	59 (7)	62 (8)
Female sex	173 (17)	779 (32)	576 (46)	3556 (37)	1333 (17)	820 (34)	827 (19)	8064 (28)
Prior CVD	0 (0)	6 (0)	513 (41)	0 (0)	7863 (100)	2431 (100)	4439 (100)	15252 (52)
Diabetes	32 (3)	2470 (100)	1249 (100)	0 (0)	676 (9)	548 (23)	202 (5)	5177 (18)
Current smoking	130 (13)	551 (22)	108 (9)	1492 (16)	735 (9)	693 (29)	1138 (26)	4847 (17)
SBP, mmHg	136 (17)	144 (16)	146 (22)	136 (17)	134 (19)	128 (20)	139 (20)	137 (18)
LDL-C$_{corr}$, mmol/L	–	2·75 (0·78)	3·00 (0·86)	2·57 (0·49)	3·68 (0·74)	3·04 (0·86)	4·74 (0·66)	3·30 (0·67)
HDL-C, mmol/L	–	1·64 (0·50)	0·94 (0·34)	1·35 (0·40)	0·96 (0·24)	1·20 (0·31)	1·19 (0·30)	1·21 (0·35)
BMI, kg/m²	26 (3)	29 (4)	28 (5)	29 (6)	–	28 (5)	26 (3)	28 (5)
eGFR, mL/min	–	–	–	75 (17)	71 (17)	–	–	73 (17)
Apo-B, g/L	–	1·16 (0·24)	1·10 (0·30)	1·08 (0·21)	1·33 (0·25)	–	1·16 (0·18)	1·17 (0·23)
On-statin								
No. of patients	504	1255	616	4802	3941	1200	2218	14536
Time to Lp(a) repeat, yrs, median	1·0	2·5	0·5	1·0	1·0	0·2	2·5	1·0
Lp(a), mg/dL, median (IQR)	7 (3-19)	8 (4-22)	11 (5-40)	11 (4-25)	13 (6-43)	11 (5-33)	11 (4-33)	11 (5-32)
<15 mg/dL	366 (73)	864 (69)	351 (57)	2912 (61)	2106 (53)	707 (59)	1268 (57)	8574 (59)
15-<30 mg/dL	59 (12)	134 (11)	60 (10)	868 (18)	548 (14)	175 (15)	321 (15)	2165 (15)
30-<50 mg/dL	43 (9)	103 (8)	73 (12)	417 (9)	439 (11)	96 (8)	375 (17)	1546 (11)
≥50 mg/dL	36 (7)	154 (12)	132 (21)	605 (13)	848 (22)	222 (19)	254 (12)	2251 (15)
% change vs. baseline (95% CI)	-1% (-6, 4)	-13% (-15, -10)	-6% (-9, -3)	2% (1, 3)	-7% (-8, -5)	9% (6, 12)	15% (13, 17)	-0·4% (-7, 7)
LDL-C$_{corr}$, mmol/L	–	1·68 (0·58)	1·73 (0·78)	1·43 (0·70) –	2·57 (0·71)	1·56 (0·77)	2·97 (0·70)	1·99 (0·70)
% change vs. baseline (95% CI)	–	-37% (-38, -36)	-41% (-43, -39)	-43% (-44, -	-29% (-30, -29)	-47% (-49, -46)	-37% (-37, -36)	-389% (-443, -
CVD incidence								
Follow-up, yrs, median (IQR)	5·6 (4·8-6·2)	4·1 (3·1-4·8)	2·4 (1·4-3·7)	2·0 (1·5-2·4)	5·4 (3·1-6·0)	0·3 (0·3-0·3)	5·3 (3·9-5·5)	3·0 (1·5-5·3)
No. of events, overall	68	170	338	234	3040	537	1364	5751
No. of events, statin arm	31	71	166	81	1428	258	568	2603

Mean (SD) or n (%), unless stated otherwise. Percentages may not sum up to 100% due to rounding. For full trial names, refer to footnote of Table 1. Total means (standard deviations) and % changes (95% confidence intervals) were calculated by pooling study-specific estimates with random-effects meta-analysis. Apo-B=apolipoprotein B. BMI=body-mass index. CVD=cardiovascular disease. eGFR=estimated glomerular filtration rate. HDL-C=high-density lipoprotein cholesterol. IQR=interquartile-range. LDL-C$_{corr}$=low-density lipoprotein cholesterol corrected for Lp(a)-cholesterol. SBP=systolic blood pressure.

Table 3 – Associations of baseline and on-statin Lp(a) with incident cardiovascular disease according to different levels of adjustment.

Lp(a) measurement / adjustment	Lp(a) 15-<30 mg/dL			Lp(a) 30-<50 mg/dL			Lp(a) ≥50 mg/dL		
	HR (95% CI)*	P value	I^2 (95% CI)	HR (95% CI)*	P value	I^2 (95% CI)	HR (95% CI)*	P value	I^2 (95% CI)
Baseline Lp(a)									
Basic adjustment: 7 trials – 29069 patients – 5751 events									
Age- and sex-adjusted	1·04 (0·91, 1·18)	0·594	43% (0, 76)	1·11 (1·00, 1·22)	0·047	0% (0, 71)	1·31 (1·08, 1·58)	0·005	73% (43, 88)
Progressive adjustment: 6 trials – 27764 patients – 5649 events									
Age- and sex-adjusted	1·03 (0·90, 1·18)	0·642	54% (0, 81)	1·10 (1·00, 1·22)	0·053	0% (0, 75)	1·30 (1·06, 1·59)	0·010	78% (52, 90)
Plus prior CVD	1·04 (0·90, 1·19)	0·6071	53% (0, 81)	1·10 (1·00, 1·22)	0·049	0% (0, 75)	1·31 (1·07, 1·60)	0·009	78% (52, 90)
Plus diabetes	1·04 (0·91, 1·19)	0·604	52% (0, 81)	1·11 (1·01, 1·23)	0·036	0% (0, 75)	1·32 (1·08, 1·61)	0·007	78% (51, 90)
Plus smoking	1·03 (0·91, 1·18)	0·613	50% (0, 80)	1·11 (1·01, 1·22)	0·034	0% (0, 75)	1·31 (1·08, 1·59)	0·007	77% (48, 90)
Plus SBP	1·03 (0·90, 1·18)	0·6364	53% (0, 81)	1·11 (1·01, 1·22)	0·031	0% (0, 75)	1·31 (1·07, 1·59)	0·008	77% (49, 90)
Plus LDL-C$_{corr}$	1·04 (0·90, 1·19)	0·6071	55% (0, 82)	1·12 (1·02, 1·24)	0·019	0% (0, 75)	1·34 (1·09, 1·65)	0·005	78% (53, 90)
Plus HDL-C	1·04 (0·91, 1·20)	0·543	54% (0, 82)	1·13 (1·02, 1·25)	0·016	0% (0, 75)	1·35 (1·11, 1·66)	0·003	77% (49, 90)
On-statin Lp(a)									
Basic adjustment: 7 trials – 14536 patients – 2603 events									
Age- and sex-adjusted	0·94 (0·81, 1·10)	0·451	18% (0, 62)	1·06 (0·94, 1·21)	0·332	0% (0, 71)	1·43 (1·15, 1·76)	0·001	62% (13, 83)
Progressive adjustment: 6 trials – 13883 patients – 2561 events									
Age- and sex-adjusted	0·93 (0·79, 1·09)	0·3667	18% (0, 63)	1·06 (0·93, 1·21)	0·351	0% (0, 75)	1·39 (1·12, 1·72)	0·002	64% (13, 85)
Plus prior CVD	0·93 (0·79, 1·09)	0·3667	18% (0, 63)	1·06 (0·93, 1·21)	0·3596	0% (0, 75)	1·39 (1·12, 1·72)	0·002	64% (13, 85)
Plus diabetes	0·94 (0·80, 1·10)	0·431	17% (0, 62)	1·07 (0·94, 1·22)	0·3071	0% (0, 75)	1·39 (1·13, 1·71)	0·002	62% (7, 84)
Plus smoking	0·94 (0·81, 1·09)	0·4152	8% (0, 77)	1·07 (0·94, 1·22)	0·30297	0% (0, 75)	1·39 (1·13, 1·71)	0·002	62% (8, 84)
Plus SBP	0·94 (0·81, 1·09)	0·412	9% (0, 77)	1·07 (0·94, 1·22)	0·30299	0% (0, 75)	1·39 (1·13, 1·71)	0·002	61% (6, 84)

Plus LDL-C$_{corr}$	0·94 (0·81, 1·10)	0·4657	13% (0, 78)	1·08 (0·95, 1·23)	0·2556	0% (0, 75)	1·41 (1·15, 1·73)	0·001	61% (3, 84)
Plus HDL-C	0·95 (0·82, 1·11)	0·5273	13% (0, 78)	1·08 (0·95, 1·23)	0·240	0% (0, 75)	1·42 (1·16, 1·74)	0·001	58% (0, 83)

556 CI=confidence interval. CVD=cardiovascular disease. HDL-C=high-density lipoprotein cholesterol. HR=hazard ratio. LDL-C$_{corr}$=low-density-lipoprotein cholesterol corrected for Lp(a)-
557 cholesterol. SBP=systolic blood pressure. *The group of patients with Lp(a) values <15 mg/dl served as reference group.

558

559 **Figure 1 – Shapes of associations of baseline and on-statin Lp(a) with incident**
560 **cardiovascular disease.**

Categories of Lp(a) were defined as <15 mg/dL, 15-<30 mg/dL, 30-<50 mg/dL, and ≥50 mg/dL. Numbers in squared brackets are means of Lp(a) values within each category. The group with the lowest Lp(a) concentration served as reference. The analysis of baseline Lp(a) involved 29069 patients (5751 events) in the age- and sex-adjusted model and 27764 patients (5649 events) in the multivariable adjusted model. Corresponding numbers for the on-statin analysis were 14536 patients (2603 events) and 13883 patients (2561 events), respectively. *The multivariable model was adjusted for age, sex, prior cardiovascular disease, diabetes, smoking, systolic blood pressure, low-density-lipoprotein cholesterol corrected for Lp(a)-cholesterol, and high-density lipoprotein cholesterol.

571 **Figure 2 – Comparative predictive value of on-statin vs. on-placebo Lp(a) for incident**
572 **cardiovascular disease.**

575 *The multivariable model was adjusted for age, sex, prior cardiovascular disease, diabetes, smoking, systolic blood pressure,
576 low-density-lipoprotein cholesterol corrected for Lp(a)-cholesterol, and high-density lipoprotein cholesterol.

577 **Figure 3 – Associations of baseline and on-statin Lp(a) with incident cardiovascular disease by individual patient characteristics.**

Baseline Lp(a) and On-statin Lp(a)

Subgroup	No. of events	HR (95% CI) comparing patients with Lp(a) ≥50 mg/dL vs. <50 mg/dL	P value for interaction	No. of events	HR (95% CI) comparing patients with Lp(a) ≥50 mg/dL vs. <50 mg/dL	P value for interaction
Age						
<60 years	2028	1.30 (1.05, 1.60)		920	1.61 (1.28, 2.01)	
60-<70 years	2714	1.23 (1.01, 1.50)	0.552	1229	1.43 (1.08, 1.89)	0.008
≥70 years	1009	1.27 (0.97, 1.68)		454	1.22 (0.93, 1.59)	
Sex						
Male	4645	1.39 (1.19, 1.63)	0.909	2098	1.56 (1.26, 1.94)	0.794
Female	1106	1.40 (1.12, 1.75)		505	1.51 (1.19, 1.91)	
Smoking status						
Other	4777	1.34 (1.14, 1.58)	0.111	2193	1.52 (1.22, 1.90)	0.247
Current	970	1.14 (0.89, 1.46)		408	1.27 (0.86, 1.87)	
Systolic blood presure						
<120 mmHg	953	1.27 (1.05, 1.54)		446	1.61 (1.19, 2.18)	
120-<140 mmHg	2172	1.32 (1.09, 1.60)	0.041	984	1.48 (1.16, 1.90)	0.957
≥140 mmHg	2618	1.31 (1.11, 1.55)		1047	1.44 (1.08, 1.93)	
LDL-C corr						
<3 mmol/L	933	1.18 (0.98, 1.43)		450	1.27 (0.97, 1.66)	
3-<4 mmol/L	1722	1.27 (1.04, 1.54)	0.250	799	1.09 (0.88, 1.35)	0.838
≥4 mmol/L	2998	1.53 (1.19, 1.97)		1314	1.76 (1.29, 2.41)	
HDL-C						
<1 mmol/L	2806	1.26 (1.03, 1.54)		1278	1.38 (1.16, 1.65)	
1-<1.3 mmol/L	1954	1.30 (1.00, 1.68)	0.776	895	1.35 (0.95, 1.92)	0.767
≥1.3 mmol/L	906	1.40 (1.18, 1.66)		394	1.66 (1.31, 2.10)	
Body-mass index						
<25 kg/m²	894	1.33 (1.01, 1.75)		382	1.70 (1.29, 2.24)	
25-<30 kg/m²	1252	1.30 (0.91, 1.87)	0.384	556	1.47 (1.08, 2.00)	0.488
≥30 kg/m²	505	1.62 (1.10, 2.38)		216	1.60 (1.08, 2.39)	

578

	Baseline Lp(a)			On-statin Lp(a)		
Subgroup	No. of events	HR (95% CI) comparing patients with Lp(a) ≥50 mg/dL vs. <50 mg/dL	P value for interaction	No. of events	HR (95% CI) comparing patients with Lp(a) ≥50 mg/dL vs. <50 mg/dL	P value for interaction
Age						
<60 years	2028	1·30 (1·05, 1·60)		920	1.61 (1.28, 2.01)	
60-<70 years	2714	1·23 (1·01, 1·50)	0·55	1229	1.43 (1.08, 1.89)	0.008
≥70 years	1009	1·27 (0·97, 1·68)		454	1.22 (0.93, 1.59)	
Sex						
Male	4645	1·39 (1·19, 1·63)	0·91	2098	1.56 (1.26, 1.94)	0.79
Female	1106	1·40 (1·12, 1·75)		505	1.51 (1.19, 1.91)	
Smoking status						
Other	4777	1·34 (1·14, 1·58)	0·11	2193	1.52 (1.22, 1.90)	0.25
Current	970	1·14 (0·89, 1·46)		408	1.27 (0.86, 1.87)	
Systolic blood presure						
<120 mmHg	953	1·27 (1·05, 1·54)		446	1.61 (1.19, 2.18)	
120-<140 mmHg	2172	1·32 (1·09, 1·60)	0·041	984	1.48 (1.16, 1.90)	0.96
≥140 mmHg	2618	1·31 (1·11, 1·55)		1047	1.44 (1.08, 1.93)	
LDL-C corr						
<3 mmol/L	933	1·18 (0·98, 1·43)		450	1.27 (0.97, 1.66)	
3-<4 mmol/L	1722	1·27 (1·04, 1·54)	0·25	799	1.09 (0.88, 1.35)	0.84
≥4 mmol/L	2998	1·53 (1·19, 1·97)		1314	1.76 (1.29, 2.41)	
HDL-C						
<1 mmol/L	2806	1·26 (1·03, 1·54)		1278	1.38 (1.16, 1.65)	
1-<1.3 mmol/L	1954	1·30 (1·00, 1·68)	0·78	895	1.35 (0.95, 1.92)	0.77
≥1.3 mmol/L	906	1·40 (1·18, 1·66)		394	1.66 (1.31, 2.10)	
Body-mass index						
<25 kg/m²	894	1.33 (1.01, 1.75)		382	1.70 (1.29, 2.24)	
25-<30 kg/m²	1252	1.30 (0.91, 1.87)	0.38	556	1.47 (1.08, 2.00)	0.49
≥30 kg/m²	505	1.62 (1.10, 2.38)		216	1.60 (1.08, 2.39)	

.8 1 1.5 2 2.5

579

580 CI=confidence interval. HDL-C=high-density lipoprotein cholesterol. HR=hazard ratio. LDL-C$_{corr}$=low-density-lipoprotein cholesterol corrected for Lp(a)-cholesterol.

Supplementary Material

Supplementary Material